<a id='b133ce38-135d-43a8-8ec0-79b07ad40455'></a>

<::A stylized image of a wheat stalk with orange grains on a light blue background, enclosed within a rounded square shape. The stalk is light blue, and the grains are a vibrant orange.::>

<a id='b5dae011-c7a8-4d26-9752-b252d8232729'></a>

ASPEN
Clinical
Nutrition
WEBINAR SERIES

<a id='7f813625-3b6f-49ce-8c32-008ea3727509'></a>

**_Nutrition Support Fundamentals Course_**
**_Parenteral Nutrition (PN) and Home PN_**

<a id='6ebff072-036a-4855-9842-51b50641a4ea'></a>

Wednesday, August 6, 2025
3:00 pm – 4:30 pm ET

<a id='19d79e82-3430-48ed-a376-606fb3ea4c38'></a>

SESSION HANDOUT
<table id="0-1">
<tr><td id="0-2"></td><td id="0-3">Page</td></tr>
<tr><td id="0-4">Accreditation Information</td><td id="0-5">2</td></tr>
<tr><td id="0-6">How to Claim CE Credit and Access CE Transcript</td><td id="0-7">3-6</td></tr>
<tr><td id="0-8">How to Access Recording and Handout</td><td id="0-9">7</td></tr>
<tr><td id="0-a">Session Slides</td><td id="0-b">8-54</td></tr>
<tr><td id="0-c">Self-Assessment Q&A</td><td id="0-d">55-57</td></tr>
</table>

<a id='cf20c839-cdd4-4ca8-8049-7aed85b40ec1'></a>

CAPTION ERROR

<a id='1ea04c4d-5723-40ae-9285-3af8b85ee02b'></a>

CAPTION ERROR

<a id='cbdc4191-4d5b-4805-a976-f1a3ea80ef2d'></a>

8401 Colesville Road, Ste 510
Silver Spring, MD 20910
301-587-6315
www.nutritioncare.org

<a id='d2d89fd5-d632-4bbb-9234-bfb39305c85c'></a>

Nutrition Support Fundamentals Course:
Parenteral Nutrition (PN) and Home PN
August 6, 2025, 3:00 pm - 4:30 pm Eastern Time

<a id='c12b72c1-4ef9-4a40-a389-a47371aef10c'></a>

**Course Goal and Target Audience:** The American Society for Enteral and Parenteral Nutrition (ASPEN) programs are designed for dietitians, nurses, pharmacists, physicians, and researchers who practice the sciences of clinical nutrition and metabolic support. This course is ideal for nutrition professionals such as dietitians, nurses, pharmacists, physicians, and others seeking a comprehensive overview of core nutrition support topics. This course and all of its parts is designed at the intermediate learning level.

<a id='fda7a98c-a602-4509-9043-a81bf5e22687'></a>

Course Objectives:
**Parenteral Nutrition (PN) and Home PN**
1. Identify current indications for parenteral nutrition
2. Discuss parenteral formula and admixture design
3. Evaluate components of parenteral nutrition monitoring and management
4. Identify key safe practice issues related to parenteral nutrition

<a id='41b9475a-2606-4cfe-b8ad-c8fad5097783'></a>

Successful Completion: CE credit must be claimed by
September 6, 2025. To obtain credit for the webinars, attendees
must participate in the entire live program and complete an evaluation
in ASPEN's eLearning Center. Certificates are stored in and can be
printed from the eLearning Center. ASPEN submits data as required
to the CPE Monitor for pharmacists. ASPEN submits physician
earned CME credit to Pars. ASPEN does not submit data to any other
credentialing organization.

<a id='ad505947-31fc-404a-b303-bb5adf252bdc'></a>

Pharmacists and physicians, please note that ASPEN will upload
earned CE credit into the appropriate system within the required
timeframe. Any credit not claimed by the deadline will not be
entered. Please provide your correct information when completing
your evaluation and claiming your CE credit. ASPEN submits only the
information that is entered by the pharmacist or physician when credit
is claimed and is not responsible for following up to obtain any
corrected information to ensure an error-free submission.

<a id='0c2a2c37-2eef-4c9e-9874-d817115b24bb'></a>

**Policies and Information:**
**Non-Commercialism.** ASPEN subscribes to the Standards for Integrity
and Independence in Accredited Continuing Education. ASPEN does
not provide programs that constitute advertisement or include
promotional materials. ASPEN does not endorse any products.

<a id='78dab7bd-7590-4275-9b96-e5ef8eec960f'></a>

**Privacy and Confidentiality.** ASPEN respects the privacy of its members and customers. Companies that receive personal information from ASPEN to execute the business of ASPEN may use information only for that purpose.

<a id='1087652c-302f-4497-8c81-dab2020cdba7'></a>

**Grievances.** Grievances must be submitted in writing to Senior
Director, Education and Research at ASPEN, 8401 Colesville Road,
Ste 510, Silver Spring, MD 20910.

<a id='2170b1b2-a146-4095-bfb5-831395f84310'></a>

Commercial Support and Sponsorship:
Commercial Support: None

<a id='54ba6dc6-509a-478c-aadf-1747dcf99469'></a>

## Accreditation Statement

<::transcription of the content
: JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION
::>

In support of improving patient care, The American Society for Parenteral and Enteral Nutrition (ASPEN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

<a id='5892f8c5-008f-4196-b00d-20409c3577e4'></a>

ASPEN designates this live activity for a maximum of 1.5 AMA PRA
Category 1 Credits ™. Physicians should only claim credit
commensurate with the extent of their participation in the activity.

<a id='81320f6c-ec1e-47a2-b9ae-c9744c3482ce'></a>

Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: JA0002345-0000-25-124-L99-P. Knowledge activity.

<a id='ce360944-cc96-4f5e-b2da-117c1262810c'></a>

Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours.

<a id='56fa439a-c753-4d10-a820-a770422f3c62'></a>

Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs.

<a id='9bc6997d-7530-49ea-8563-d22ff54659e6'></a>

Commission on
Dietetic Registration
eat right. the credentialing agency for the
Academy of Nutrition and Dietetics

<a id='37aedff8-abd1-4ee7-80e6-70304bcfe9f0'></a>

Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (One IPCE credit = One CPEU).
If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation in contact hours (One 60 minute hour = 1 CPEU).
RD's and DTRs are to select activity type 102 in their Activity Log. Sphere and Competency selection is at the learner's discretion.

<a id='ca452257-4845-425d-8daf-b8d7f1869b41'></a>

<::transcription of the content
: stylized 'A' or triangle logo with text "IPCE CREDIT™"::>

This activity was planned by and for the healthcare
team, and learners will receive 1.5
Interprofessional Continuing Education (IPCE)
credit for learning and change.

<a id='7ab32770-f320-4600-b7d7-2203a22aa746'></a>

**Disclosures and Relevant Financial Relationships for Faculty and**
**Planning Committee Members**
ASPEN staff have no relevant financial relationships with ineligible
companies.

<a id='b789f9f1-2544-4a03-b475-67dbbe9bc4af'></a>

<table id="1-1">
<tr><td id="1-2">Name</td><td id="1-3">Role</td><td id="1-4">Commercial Entity</td></tr>
<tr><td id="1-5">Phil Ayers</td><td id="1-6">Consultant</td><td id="1-7">American Regent</td></tr>
<tr><td id="1-8"></td><td id="1-9">Consultant</td><td id="1-a">B. Braun</td></tr>
<tr><td id="1-b"></td><td id="1-c">Consultant and Speaker</td><td id="1-d">Fresenius Kabi USA, LLC</td></tr>
</table>

<a id='6ad0cf5a-4914-416c-9538-f8a426b05ff1'></a>

All relevant financial relationships have been mitigated.

<a id='7aed6cf0-44a6-4c3b-be8c-1b3c8964aec5'></a>

Note: an ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For specific examples of ineligible companies visit accme.org/standards.

<a id='8d4a7d98-32be-439f-9cac-7e159db3a56b'></a>

Financial relationships are relevant if the following three conditions are met for the prospective person who will control content of the education:

*   A financial relationship, in **any amount**, exists between the person in control of content and an ineligible company.
*   The financial relationship existed during the past **24 months**.
*   The content of the education is related to the products of an ineligible company with whom the person has a financial relationship.

<a id='9b164501-d67c-49f3-8093-a59d8ab735fc'></a>

CAPTION ERROR

<a id='faa1f02a-a89b-4e20-9e9a-391f61cb1ef3'></a>

Nutrition Support Fundamentals Course: Summer 2025
CE Credit Deadlines

<a id='344931d3-57d5-4093-a3c5-c3bca02537df'></a>

<table id="2-1">
<tr><td id="2-2">Webinar Topic</td><td id="2-3">CE Credit Deadline*</td></tr>
<tr><td id="2-4">Fluids and Electrolytes</td><td id="2-5">August 30, 2025</td></tr>
<tr><td id="2-6">Parenteral Nutrition (PN) and Home PN</td><td id="2-7">September 6, 2025</td></tr>
<tr><td id="2-8">Nutrient Deficiencies and Malnutrition Assessment</td><td id="2-9">September 13, 2025</td></tr>
<tr><td id="2-a">Enteral Nutrition (EN) and Home EN</td><td id="2-b">September 19, 2025</td></tr>
<tr><td id="2-c">Enteral Nutrition and Parenteral Nutrition Access</td><td id="2-d">September 27, 2025</td></tr>
<tr><td id="2-e">Gastrointestinal (GI) Disorders</td><td id="2-f">October 4, 2025</td></tr>
<tr><td id="2-g">Acid Base</td><td id="2-h">October 10, 2025</td></tr>
<tr><td id="2-i">Critical Care and Statistics</td><td id="2-j">October 12, 2025</td></tr>
<tr><td id="2-k">Ethics for the Nutrition Professional</td><td id="2-l">October 17, 2025</td></tr>
<tr><td id="2-m">Pediatric and Neonatal Nutrition Support</td><td id="2-n">October 19, 2025</td></tr>
</table>

<a id='c5669741-200d-4147-bc46-390c17bd1258'></a>

*Please note that CE credit cannot be claimed after the deadline

<a id='5eba270e-6290-4c98-81e7-e7c267e54e27'></a>

CAPTION ERROR

<a id='252832b4-4cf9-43a7-b431-25207312fdee'></a>

Nutrition Support Fundamentals Course: Summer 2025
CE Credit – Important Information

<a id='39e8db09-3c02-40a5-b557-2367ff87116e'></a>

**Please note the following:**
* CE credit CANNOT be claimed for missed webinars. You must attend the live webinar broadcast at the scheduled time to claim CE credit for that webinar.
* CE Credit is calculated on a per webinar attended basis. If you miss a webinar, you can still receive CE credit for other webinars attended.
* CE credit will be granted for each webinar attended up to a maximum of 15.5 CE credits for the entire course.
* You must complete the evaluation after each webinar to receive CE credit for that webinar.
* You must complete the Overall Conference Evaluation to receive your course certificate. This form will be available at the end of the course.

<a id='c92a40e7-e6fa-4203-ab69-fd9d8bd5182c'></a>

**IMPORTANT INFORMATION FOR PHARMACY PARTICIPANTS!**
Pharmacy participants should claim CE credit as soon as possible following each session attended.

Due to Accreditation Council for Pharmacy Education (ACPE) and National Association of Boards of Pharmacy (NABP) guidelines, ASPEN is required to submit CE credits claimed by Pharmacy participants within 60 days of the end of a session. Because this course takes place over several weeks with multiple webinars, **Pharmacy participants are strongly encouraged to claim CE credit immediately following each session**, so you do not forget or miss claiming credit within the required 60-day period.

Pharmacy participants are required to submit their birthdate (MM/DD), submit their NABP ID #, and complete the session evaluation to claim CE credit. For more information or to create your NABP ID, please visit [www.nabp.net](www.nabp.net).

ASPEN is not responsible for late or incorrect submissions by the participant.

<a id='f3245dcc-e115-460a-ab5a-6815cc66cd77'></a>

CAPTION ERROR

<a id='cef49ced-18e6-40ef-bbfa-b175c4c0a84f'></a>

Nutrition Support Fundamentals Course: Summer 2025
How to Claim CE Credit

<a id='0267d228-6d6a-4f02-92e0-c8df20cc98b7'></a>

## Log into eLearning Center
Step 1: Log into the ASPEN eLearning Center at https://aspen.digitellinc.com.
(Your login is the same email and password you use for the main ASPEN website.)

<a id='17fe0828-2e03-41cd-8679-98cde4760610'></a>

## To Claim CE Credit
Step 2: Click on the "**My Account**" button at the top right of the screen.

Step 3: Click "**Live Events**" in the dropdown menu.

Step 4: Find the **Nutrition Support Fundamentals Course Summer 2025**. Under the course title and dates, "**Attend Event**" (note: you will see "**Review Event**" after the course ends).

Step 5: Click on "**Evaluations**" in the menu under the course title and dates.

Step 6: Click on the "**Take Evaluation**" button under the appropriate session heading.

After completing the evaluation, you should see a statement of completion with the date and time. The CE credit will now appear on your CE transcript.

<a id='ef470a78-0ad9-4f5b-b7bd-4bd85f466984'></a>

CAPTION ERROR

<a id='872ffd35-6a19-4bc5-822e-e19fae57fb76'></a>

Nutrition Support Fundamentals Course: Summer 2025
How to View CE Credit and Access CE Transcript

<a id='65f41c50-851a-4cde-b203-190c72c9dd4f'></a>

### To View CE Credit
Step 1: Click on the "**My Account**" button at the top right of the screen.

<a id='6b14f7e7-bb16-4405-9e2e-0e0f1e1a1204'></a>

Step 2: Click “**CE Transcript**” in the dropdown menu.

<a id='e8ea4b54-5495-48f1-83ee-58a1d389d011'></a>

Step 3: Find the Nutrition Support Fundamentals Course Summer 2025 and click on the **Course Title**. You should now see the CE credit listed for each session for which you have completed the session evaluation.

<a id='a44da5ef-55ec-431a-a283-e12ac8340d79'></a>

<::A screenshot of the 'aspen | eLearning Center' website interface. The page displays a header with the logo and top navigation links (My Account, Inbox, Notifications, Cart, Support, Search). A left-hand navigation menu includes links such as My Courses, My Packages, My Publications, CE Transcript, Redeem Access Code, Orders, and Profile Information. The main content area shows a 'Nutrition Support Fundamentals Course Summer 2023' section, which presents a tabular display of course credits. The table includes columns for Name, CE Credit, Credits, Type, Completed On, and Certificate. Below the table, there is an 'Overall Evaluation' button with a checked checkbox. : webpage_screenshot::>
aspen | eLearning Center

My Account
Inbox
Notifications
Cart
Support
Search

My Courses

My Packages

My Publications

CE Transcript

Redeem Access Code

Orders

Profile Information

Nutrition Support Fundamentals Course Summer 2023

Name
CE Credit
Credits
Type
Completed On
Certificate

Fluids and Electrolytes
1.50
Other
2023-07-27 15:35:53
-
Review Answers

Parenteral Nutrition (PN) and Home PN
1.50
Other
2023-07-27 15:49:54
-
Review Answers

Total
3
Other

option Overall Evaluation: [x]

<a id='9c18586b-1330-4065-b989-eb112fbee90b'></a>

<u>**To Access CE Transcript**</u>\nPlease note that you will not be able to print your CE transcript until the end of the course. After the last course session, follow the steps below to access your transcript.

<a id='6dd46b96-ab28-4895-8545-7d42d133d907'></a>

Complete steps 1-3 above.

<a id='e26356ab-999e-4959-aebf-f1f2d401aa09'></a>

Click on the "**Overall Evaluation**" button at the bottom of the course information and complete the overall evaluation. This button will only work after the last course session.

<a id='7331d191-cb70-42a1-bfbb-b2328058eb7d'></a>

A button that says "Print Transcript" should appear at the bottom of the course information. Click on the "**Print Transcript**" button to print a copy of your CE transcript. All course sessions for which you completed the individual webinar evaluation and the corresponding CE credit will appear on your final course transcript. The transcript will be saved in your eLearning Center account.

<a id='8a423fb2-acde-494b-9d2b-068a152b5f53'></a>

My Chapter Events
My Courses
My Packages
My Publications
CE Transcript

**Nutrition Support Fundamentals Course 2019**

<table><thead><tr><th>Name</th><th>Credits</th><th>Type</th><th>Completed On</th><th>Certificate</th></tr></thead><tbody><tr><td>Test Taking Tips, Nutrient Deficiencies, Malnutrition Assessment</td><td>2.00</td><td>Dietitian</td><td>2019-08-15 12:09:34</td><td>Review Answers</td></tr><tr><td>Total</td><td>2.00</td><td>Dietitian</td><td></td><td></td></tr></tbody></table>

Print Transcript

<a id='1a963f33-a729-44f2-a861-cc7f32fdfd81'></a>

CAPTION ERROR

<a id='bfe43f0c-be04-47b4-8640-0ddefce6ea48'></a>

Nutrition Support Fundamentals Course: Summer 2025
How to Access Recording and Handout

<a id='c7f47e45-adca-4321-892f-a2ba3527cdb1'></a>

Step 1: Log into the ASPEN eLearning Center at https://aspen.digitellinc.com.
(Your login is the same email and password you use for the main ASPEN website.)

<a id='b6cf452c-c32e-4fb5-9258-013f33264c92'></a>

Step 2: Click on the "My Account" button at the top right of the screen.

<a id='036532a1-dd4e-4f7b-bac6-ab51c80111aa'></a>

Step 3: Click “Live Events” in the dropdown menu.

<a id='347786f8-512b-49b1-b046-9d48c5f0ef45'></a>

Step 4: Find **Nutrition Support Fundamentals Course Summer 2025**. Under the course title and dates, click on "**Attend Event**" (note: you will see "**Review Event**" after the course ends).

<a id='d6cfbc90-15ee-4ceb-8bc0-862a6883b968'></a>

Step 5: Click on "Recordings" in the menu under the course title and dates.

<a id='84d15755-2f53-4714-bebc-f0f4b201de37'></a>

Step 6: Find the appropriate webinar session and click on the "View Archive" button.

<a id='4e0b4adc-bb38-4ad0-ae8d-f60524697ea8'></a>

To listen to the recording, **click inside the webinar player**.

<a id='d62e2c4b-9f6f-4942-bc56-bd6ed14981c1'></a>

To download the recording, click "**Download MP3**" underneath the webinar player on the right side of the screen.

<a id='c4bf2b2a-9cfd-42b9-a890-baac54d76134'></a>

To download the handouts, click on the "Download Handout" underneath the webinar player on the right side of the screen.

<a id='78837a91-4d22-4015-bc37-6ea8a692a1d0'></a>

*The webinar recording will be available in the eLearning Center within 3 business days following the scheduled broadcast date. Please note that you cannot claim CE credit if you did not attend the live webinar broadcast and only listen to the webinar recording.

<a id='85b80a1d-ffb3-4577-97a2-378c6864c752'></a>

**If you miss the live webinar broadcast, you can still access the webinar handout and recording in the eLearning Center.

<a id='a3df484e-2549-4592-a10c-f844b512bd28'></a>

CAPTION ERROR

<a id='da600c47-ce8e-409a-a75b-c185a3adb9a0'></a>

CAPTION ERROR

<a id='8aefe097-ecc4-43ad-8790-fa52ae9c6f00'></a>

CAPTION ERROR

<a id='83aad0fa-7bc4-44c8-9174-1699173062e3'></a>

# Nutrition Support Fundamentals Course

## Parenteral Nutrition (PN) and Home PN

August 6, 2025 • 3:00 – 4:30 PM ET

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='bdad56c9-7098-43cd-a684-511dfeabf610'></a>

1

<a id='f22da82a-e324-4c29-9c7a-2ea1a055f708'></a>

Using the Webinar Player

<::
Fluids and Electrolytes - Google Chrome
live2b.digitell.io/session/aspen-5526vnyy/interface/r

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

Info Panel [x]

Fluids and Electrolytes
Jul 26, 2022 3:00pm - 4:30pm EST

ASPEN's Nutrition Support Fundamentals Course (NSFC) provides a comprehensive overview of nutrition support therapy. The course can be used as a tool for helping you identify personal knowledge gaps to further identify future areas of learning. Whether you are preparing for the certification examinations or seeking additional professional growth in nutrition

option Info Panel: [x]
option Chat: [ ]
option Polling: [ ]
option Resources: [ ]
option Questions: [ ]
option Request Support: [ ]
: illustration::>

Click on the tabs on the left side of your screen to access the webinar player functions.

*   **Info Panel**: View session and presenter information
*   **Chat**: Communicate with other session attendees
*   **Polling**: Answer polling questions
*   **Resources**: Download handout and reference material
*   **Questions**: Submit questions for presenters

For technical assistance, click Request Support.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral Enteral Nutrition

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='b0fe1447-c3f2-4502-80ad-1f1147b8c256'></a>

2

<a id='aa39c6fc-cb14-4183-a4e3-a4bd26b603ae'></a>

CAPTION ERROR

<a id='598eadf8-7e18-4280-bdb6-b2331b4bcaf9'></a>

8

<a id='a050bd79-2e10-46a1-a3f3-0fb886b6e9e3'></a>

CAPTION ERROR

<a id='0c5949d8-8094-4483-8ac9-018b611bc35d'></a>

<::headshot of Phil Ayers
: figure::>

Phil Ayers, PharmD, BCNSP, FMSHP, FASHP, FASPEN

Chief, Clinical Pharmacy Services
Mississippi Baptist Medical Center
Clinical Associate Professor
University of Mississippi School of Pharmacy
Jackson, Mississippi

<::Aspen logo with text: LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION American Society for Parenteral and Enteral Nutrition
: figure::>

<a id='433bebfd-c89c-472b-a22f-39400f986bd3'></a>

3

<a id='47179c94-5b9a-409c-b5ab-68486fb224a0'></a>

Disclosures

*   American Regent-Consultant
*   B. Braun-Consultant
*   Fresenius Kabi-Speaker/Consultant

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

4

<a id='20f1e0d4-7b9a-4b3d-996d-8a8885cf1089'></a>

spen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='d59fac02-c88c-48c3-a087-b5f3a21df797'></a>

CAPTION ERROR

<a id='f4f90162-2828-4e8c-8605-4c1c7d328dc9'></a>

2

<a id='1f12060e-abcc-4b73-a630-0f22adaca960'></a>

CAPTION ERROR

<a id='f4e3ced9-79fe-4108-9554-cd3c8a61ff80'></a>

CAPTION ERROR

<a id='6603b4a1-ddf7-47d4-93ca-1fcf653ddd16'></a>

©2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

# Learning Objectives

*   Discuss indications for parenteral nutrition (PN)
*   Review parenteral nutrition prescription process
*   Develop a proper plan for PN monitoring and management
*   Identify issues related to safe practice

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='a215bbd9-4202-4354-a718-4dac33ef8be9'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='fbaebed2-a754-4e20-9e4a-d0e9bf46c663'></a>

CAPTION ERROR

<a id='ac33fe28-c59f-46c9-b361-45490c046a7c'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
Parenteral Nutrition Process

<::The visual content is a flowchart titled "INTERDISCIPLINARY NUTRITION CARE" illustrating the Parenteral Nutrition Process. It shows various roles and their associated steps, with arrows indicating the flow.

**Roles and Steps:**

*   **Dietitian, Nutrition Support Team:**
    *   **Assess**
        *   Review patient data
        *   Provide nutrition assessment
        *   Recommend nutrition care plan (PN)
        *   Communicate with prescriber
    *   **Monitoring**
        *   Mechanical
        *   Metabolic
        *   Patient outcome

*   **Prescriber:**
    *   **Ordering PN**
        *   Standardized order form

*   **Pharmacist:**
    *   **PN Order Verification/Review**
        *   Dosing
        *   Appropriateness
        *   Stability & Compatibility
    *   **Compounding**
        *   Sterile preparation
        *   Product testing

*   **Nurse, Patient Caregiver:**
    *   **Administer the PN**
        *   Order verification
        *   Access
        *   Infusion
        *   Infection control

*   **Pharmacy Technician:**
    *   **Dispense PN**
        *   Labeling
        *   Delivery
        *   Storage

**Central Element:**

*   **Documentation**
    *   Medical record
    *   Transitional care

**Flow of Process (indicated by arrows):**

1.  Assess leads to Ordering PN and Documentation.
2.  Ordering PN leads to PN Order Verification/Review and Documentation.
3.  PN Order Verification/Review leads to Compounding and Documentation.
4.  Compounding leads to Dispense PN and Documentation.
5.  Dispense PN leads to Administer the PN and Documentation.
6.  Administer the PN leads to Monitoring and Documentation.
7.  Monitoring leads back to Assess.
8.  Documentation is connected to all major process steps (Assess, Ordering PN, PN Order Verification/Review, Compounding, Dispense PN, Administer the PN, Monitoring).
: flowchart::>

Boullata JI JPEN J Parenter Enteral Nutr. 2012;36:10-13S
<::The visual content is a logo for "aspen" (American Society for Parenteral and Enteral Nutrition) with the tagline "LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION".
: logo::>

<a id='5f6ae49a-f066-465a-8a8f-df03ab242a43'></a>

CAPTION ERROR

<a id='57f1742d-4d7f-446b-81e2-70584578dec7'></a>

CAPTION ERROR

<a id='a6f80965-26c6-4adf-9ac1-4d97c3b1c4f6'></a>

CAPTION ERROR

<a id='642dd582-6754-40db-882d-ba8c1b25e98c'></a>

8/5/2025

<a id='94d210b8-7e6f-44e4-87ff-7d1c72da6af0'></a>

# Parenteral Nutrition

## Peripheral PN
*   Short term
*   May be limited by venous access
*   Maximum osmolarity
    *   900 mOsm/L
    *   Dextrose concentration 5-10%
    *   Amino acid concentration ~3%
*   Large amount of fluids needed to provide nutrition
*   Not suitable in RF, CHF
*   Do potential complications outweigh benefits?

## Central PN
*   Long term indefinite duration
*   Infused via CVC
*   Hyperosmolar solution rapidly diluted
*   Can be concentrated
*   Used for many applications
    *   Home infusion, ICU

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='f0699c18-6eb2-4d37-8209-f11cd1ff6e1c'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='18c44232-48c0-4047-a22f-77b47113cda3'></a>

2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='df4cfa24-bd5e-4b80-a917-421c28b29187'></a>

CAPTION ERROR

<a id='bf21d5a2-8905-42d8-b600-4a9e94e47a92'></a>

Indications for PN

*   Contraindication to EN or access
*   Impaired absorption or loss of nutrients
*   Mechanical bowel obstruction
*   Need for bowel rest
*   Motility disorders
*   Inability to achieve or maintain enteral access

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

Worthington P, Balint J, Bechtold M, etal. When is Parenteral Nutrition Appropriate? JPEN. 2017 Mar;41(3):324-77.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='33b83204-13f6-46a1-af55-f15682635747'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='bb9dd99d-0ecc-4a04-9fad-fb85cf0533cc'></a>

CAPTION ERROR

<a id='09179fec-b542-44f5-be86-e73f8980accc'></a>

CAPTION ERROR

<a id='01e5a639-542f-4549-aaed-33f64baa069b'></a>

11

<a id='4fa671bf-4bd3-4a32-90ed-6cf49a224185'></a>

8/5/2025

<a id='6c576e72-2276-47c9-9dcd-0a1794b30e88'></a>

## PN Criteria

*   Well nourished stable adult – wait 7 days
*   Nutritionally-at-risk – wait 3-5 days
*   Baseline moderate or severe malnutrition – as soon as feasible

*   Delay in those with severe metabolic instability
    *   Address electrolyte abnormalities
    *   Address hypovolemia, shock, hypoxia
*   CVC available?
*   Duration of therapy exceeds 5-7 days

Worthington P, Balint J, Bechtold M, etal. When is Parenteral Nutrition Appropriate? JPEN. 2017 Mar;41(3):324-77.

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='94224a0d-a3f2-442e-babb-cfb82fd2cfba'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='3a3d12a5-c89c-4d86-aa74-f236b38ffb20'></a>

CAPTION ERROR

<a id='096fa1fe-c72f-44b7-8820-02fd46190ad6'></a>

# PN Delivery Systems

*   Compounded PN
    *   2 in 1
        *   Amino acid + Dextrose
        *   Intravenous lipid emulsion (ILE) piggybacked
            *   12 hour hang time
        *   Improved visual inspection
        *   Filter with 0.2 micron filter and 1.2 micron for ILE
*   Total Nutrient Admixture (TNA) or 3 in 1
    *   Amino acid + Dextrose + ILE in same bag
    *   Easier for home administration
    *   Filter with 1.2 micron filter
    *   24 hour hang time

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='c4e8cbf9-37f0-4e1d-a417-a700a9937bf0'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='bb210773-a32d-40b0-8efa-c6cd4dbdef87'></a>

CAPTION ERROR

<a id='0e54c1f4-565c-40c4-bbee-ae3b59c3a822'></a>

CAPTION ERROR

<a id='d9dd38eb-d1e0-44e3-be58-9adda7402a6f'></a>

5

<a id='3f34b888-7767-4700-8b62-61108d4c9503'></a>

CAPTION ERROR

<a id='88d32024-31bb-49c6-b338-1c95e2083997'></a>

Compounded PN

<::transcription of the content
: figure::>

2 in 1 PN

<::transcription of the content
: figure::>

3 in 1 PN

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='47c51ec4-64b5-4e7c-9fad-2e289f16ac02'></a>

11

<a id='2ae0cf6f-a21d-498f-83bd-c1f28df48758'></a>

Standardized Commercially Available PN (SCAPN)
aka Multi-chamber Bag (MCB)

*   Clinimix®
    *   Sulfite free, sterile, non-pyrogenic, sterile two chamber solution
    *   1 and 2 liter dual chamber container
        *   Dextrose chamber with or without calcium
        *   Amino acids with or without electrolytes
*   Kabiven®/PeriKabiven®
    *   Sterile, hypertonic three chamber container
    *   Available in 4 sizes
*   Recommend activation by pharmacy
*   Limited amounts of protein and electrolytes provided
*   Follow manufacturer specific recommendations
*   Need to add MVI and trace elements

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='3a5f8714-c228-4030-87c9-d845a9e1fe69'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='a0b255c9-1658-4f6f-8378-cf87af971146'></a>

CAPTION ERROR

<a id='1504f0c3-d2bc-43ff-83f8-4933ef93df0e'></a>

13

<a id='c93e826d-b7ab-4ca7-a956-b04e2d16b8ab'></a>

CAPTION ERROR

<a id='f187958c-45e4-4f1f-80be-0f376886904a'></a>

CAPTION ERROR

<a id='797bbd3f-fbab-4e4e-8bdb-ff02b06e822e'></a>

MCB

<::transcription of the content
: Dextrose chamber
(with or without calcium)

Peel seal

Amino acid chamber
(with or without electrolytes)

KABIVEN
1540 mL
FRESENIUS KABI
CENTRAL INFUSION

READ THIS

Administration port

Additive port (lipid)

Injection port
(medications,
trace elements,
multiple vitamins)::>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='50ab0d0d-b39e-46df-9543-a7015194ac35'></a>

13

<a id='f02e11be-081b-412c-b16d-fec29dbd2e59'></a>

# Carbohydrate Provision

*   Preferred fuel for CNS, blood cells, granulation tissue
*   Largest amount of calories in PN from carbohydrates
*   Dextrose
    *   3.4 kcal/gram
    *   pH ranging from 3.5 – 6.5

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='bc399677-5c09-46e2-9ea4-cec762f26ce3'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='c1539389-eac2-4aaa-8d89-4f1b9df33321'></a>

CAPTION ERROR

<a id='bcc12de2-18d5-4f70-b53f-aec6874f105c'></a>

CAPTION ERROR

<a id='24018e60-7f49-47f5-8274-7398c253e192'></a>

7

<a id='246d1c06-cce6-49e4-9454-312030e97946'></a>

CAPTION ERROR

<a id='29e439d6-0c5a-477b-83bf-867559d45317'></a>

## Protein Provision

*   Necessary for synthesis of structural protein, growth, enzymatic function
*   Amino acid solution (crystalline)
    *   4 kcal/gram
    *   Acetate or chloride load from AA solution
    *   Assumed to be 16% nitrogen
        *   6.25g protein = 1g nitrogen
*   Standard 8.5% or 10%
*   Concentrated 15% or 20%
    *   May benefit volume restricted patients

©2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='ab7b6940-18cc-4d02-91ca-0c61a4d85d03'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='22e1a1f7-5f1a-41ae-afc9-3f391e09d9e0'></a>

15

<a id='ab4d818e-9e6b-42c4-a915-1819ae04e51e'></a>

Table 2. Evolution of ILEs.
<table id="14-1">
<tr><td id="14-2"></td><td id="14-3">Generation of ILE</td><td id="14-4">Description</td><td id="14-5">Rationale for design</td><td id="14-6">Other potential benefits</td></tr>
<tr><td id="14-7"></td><td id="14-8">First Second</td><td id="14-9">Single-oil formulation using either SO or safflower oil Two-oil formulation including SO and MCT</td><td id="14-a">Source of EFA and energy Lower SO content</td><td id="14-b">Compatibility information available with commonly used medications Reducing the @-6 FA content</td></tr>
<tr><td id="14-c"></td><td id="14-d"></td><td id="14-e"></td><td id="14-f"></td><td id="14-g">More stable ILE product with MCT oil" MCTs accumulate less in adipose tissues and liver and are cleared faster with minimal peroxidation MCTs do not produce proinflammatory mediators</td></tr>
<tr><td id="14-h"></td><td id="14-i">Third</td><td id="14-j">Two-oil ILE using SO and OO, resulting in a reduced amount of EFA (@-6 FAs)</td><td id="14-k">Reduce SO content but still provide enough EFA</td><td id="14-l">Higher amounts of monounsaturated FAs have a lower amount of peroxides produced during oxidation than PUFAs Oleic acid in OO is not metabolized to mediators of inflammation and immunity Potentially well suited for patients who are at risk of immune suppression or are immune compromised</td></tr>
<tr><td id="14-m"></td><td id="14-n">Fourth</td><td id="14-o">Four-oil ILE including SO, MCT, OO, and FO</td><td id="14-p">Designed to include an optimal level of @-6 to @-3 FAs and includes FO and OO</td><td id="14-q">Lower ratio of @-6 to @-3 FA (reduced SO dose) FO included for critically ill and surgical patient populations OO may be beneficial in those with immune disorders</td></tr>
<tr><td id="14-r"></td><td id="14-s"></td><td id="14-t">FO</td><td id="14-u">Source of FAs and energy in infants and children with IFALD</td><td id="14-v">May reverse IFALD</td></tr>
</table>
©2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
Nutr Clin Pract 2020;00:1-14.

<a id='d4fa2db9-6f41-4324-bcc9-30cc25f6ad3f'></a>

CAPTION ERROR

<a id='2e97395d-6cc8-4b19-9029-c77da2d9ccd1'></a>

CAPTION ERROR

<a id='b34a308b-7b37-44c7-b73e-942294f211ba'></a>

CAPTION ERROR

<a id='70c75ae0-3369-4495-815f-527754fe20e4'></a>

8/5/2025

<a id='394de395-9179-47db-a833-0bf79d5bb53c'></a>

# Fat Provision

*   Maintains cellular membranes, serves as precursor of prostanoids and leukotrienes
*   Intravenous Lipid Emulsion (ILE)
    *   10 kcal/gram
    *   Glycerin makes formulation isotonic
    *   Egg phospholipid acts as emulsifier
        *   Contains phosphate – 1.5 mmol/100 mL
    *   Contain small amounts of vitamin K from soy or olive oil
    *   10% and 20% okay to administer via central or peripheral line
    *   Soybean component provides essential fatty acids
    *   Must be infused with 1.2 micron filter

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='d5cd4b09-0ff8-41a9-bff2-1e53ef4c1c8d'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='b61dbaa3-6da4-4cfd-a2b4-51a8fa71ad19'></a>

CAPTION ERROR

<a id='173de5db-b19f-4bb5-8564-4dd320b501ef'></a>

Fat Provision

<a id='1f38fbdb-a0a0-4b84-9a67-c71270e4b900'></a>

100% Soybean based ILE
* 10% - 1.1 kcal/mL
* 20% - 2 kcal/mL
* 30% - 3 kcal/mL
  * Only for 3-in-1 compounding

Clinolipid 20%
Olive oil
Soybean oil

Smoflipid 20%
* 2 kcal/mL
* Caution with fish allergy
* Soybean oil – 6 g/100 mL
* MCT – 6 g/100 mL
* Olive oil – 5 g/100 mL
* Fish oil – 3 g/100 mL

<a id='db507c46-d76b-4c87-ad6f-75b072696e5a'></a>

* Caution with soybean or egg allergies for 3 ILES
* If no h/o previous ILE or medications suspended in ILE
* Test dose may be done 1 mL/minute for 30 minutes
* If tolerated may advance to prescribed rate
* Piggybacked ILE – 12 hour hang time
* TNA – 24 hour hang time

<a id='5a0ce2be-bcfb-4c81-9b32-c204abc2aac7'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='c1e2b507-604d-468e-8a4d-24674770d0a9'></a>

CAPTION ERROR

<a id='749de12f-1870-4474-a2a1-d8e9b6b82bdc'></a>

16

<a id='4cd285d7-ea70-4452-a1eb-08ac0eb8469d'></a>

CAPTION ERROR

<a id='8d995558-b12c-4011-b4a1-7bc77e228382'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='248a5d2e-a7ea-4dc9-a90a-c2a10e135a1a'></a>

CAPTION ERROR

<a id='f8684129-c7e8-4b21-823e-47ca0c9e110d'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
<table id="16-1">
<tr><td id="16-2"></td><td id="16-3">Soybean Oil (Intralipid)</td><td id="16-4">Soy, MCT, Olive, Fish Oils (SMOFlipid)</td><td id="16-5">Fish Oil (Omegaven)</td><td id="16-6">Olive/Soybean Oils (Clinolipid)</td></tr>
<tr><td id="16-7">Indications</td><td id="16-8">Source of calories and essential fatty acids. Prevention of Essential Fatty Acid Deficiency (EFAD)</td><td id="16-9">Source of calories and essential fatty acids.</td><td id="16-a">Source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC)</td><td id="16-b">Source of calories and essential fatty acids.</td></tr>
<tr><td id="16-c">Approved Populations</td><td id="16-d">Adult and Pediatric</td><td id="16-e">Adult</td><td id="16-f">Pediatric</td><td id="16-g">Adult</td></tr>
<tr><td id="16-h">Contraindications</td><td id="16-i">Disturbances of normal fat metabolism such as pathologic hyperlipemia, lipid necrosis, or acute pancreatitis accompanied by hyperlipidemia</td><td id="16-j">Hypersensitivity to fish, egg soybean or peanut protein. Severe hyperlipidemia or severe disorders of lipid metabolism (serum triglycerides > 1000mg/dl)</td><td id="16-k">Hypersensitivity to fish or egg protein or any of the active ingredients or excipients. Severe hemorrhagic disorders. Severe hyperlipidemia or severe disorders of lipid metabolism (serum triglycerides > 1000mg/dl)</td><td id="16-l">Hypersensitivity to egg or soybean proteins or to any of the ingredients including excipients. Severe hyperlipidemia or severe disorders of lipid metabolism (serum triglycerides > 1000mg/dl)</td></tr>
<tr><td id="16-m">Potential Uses</td><td id="16-n">-Short term use (<2 weeks) -Normal LFTs -Treatment of EFAD</td><td id="16-o">-Long term use -Elevated LFTs -Elevated triglyceride -Inflammatory states</td><td id="16-p">-PNAC (IFALD)</td><td id="16-q">-Long term use -Elevated LFTs -Elevated triglyceride</td></tr>
<tr><td id="16-r">Dosing</td><td id="16-s">-Adult: <1g/kg/d for stable/home/long term.-Do not exceed 2.5g/kg/d-ICU: Consider withholding first week-Pediatrics: 0.5-3g/kg/day</td><td id="16-t">-Adult: 1-2g/kg/d not to exceed 2.5g/kg/d-Pediatrics: (off label) 1-3g/kg/d</td><td id="16-u">-Pediatric: 1g/kg/day (maximum dose)</td><td id="16-v">Adult: 1-1.5g/kg/d not to exceed 2.5g/kg/d</td></tr>
<tr><td id="16-w">Administration</td><td id="16-x">-Use a 1.2 micron filter-Use a non-vented infusion set or close vent on vented set-Use a non-DEHP set</td><td id="16-y">-Use a 1.2 micron filter-Use a non-vented infusion set or close vent on vented set-Use a non-DEHP set</td><td id="16-z">-Use a 1.2 micron filter-Use a vented infusion set when infused from the bottle-Use a non-DEHP set</td><td id="16-A">-Use a 1.2 micron filter-Use a non-vented infusion set or close vent on vented set-Use a non-DEHP set</td></tr>
</table>
THE SCIENCE AND
E OF CLINICAL NUTRITION
steral and Enteral Nutrition

<a id='480737d0-fc0f-4f2e-83fa-32b2a4e37434'></a>

CAPTION ERROR

<a id='9e009c4f-27fa-4708-9911-460a8974b4af'></a>

0
<table id="16-B">
<tr><td id="16-C">Special Report</td><td id="16-D">aspen (logo)</td></tr>
<tr><td id="16-E">Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper</td><td id="16-F">Nutrition in Clinical Practice Volume 0 Number 0 October 2020 1-11 ©2020 American Society for Parenteral and Enteral Nutrition DOI: 10.1002/ncp.10587 wileyonlinelibrary.com</td></tr>
<tr><td id="16-G">Patricia Worthington, MSN, RN, CNSC¹; Kathleen M. Gura, PharmD, BCNSP, FASHP, FASPEN, FPPA, FMSHP²; Michael D. Kraft, PharmD, BCNSP³; Reid Nishikawa, PharmD, FASPEN⁴; Peggi Guenter, PhD, RN, FAAN, FASPEN⁵; Gordon S. Sacks, PharmD, BCNSP, FASPEN, FCCP⁶; and the ASPEN PN Safety Committee¹</td><td id="16-H">WILEY</td></tr>
</table>
© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='df3f43fe-1eb8-43bf-8c81-31a6c94bd017'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

---

Nutrition in Clinical Practice
Volume 0 Number 0
October 2020 1–11
© 2020 American Society for
Parenteral and Enteral Nutrition
DOI: 10.1002/ncp.10587
wileyonlinelibrary.com
WILEY

<a id='3f3158cd-a070-4ce1-82e1-ac2a5a9075b4'></a>

20

<a id='0bdeafaa-353d-4268-8261-bc58dad6492c'></a>

17

<a id='32c3fc78-50e1-4ebf-ab43-7ea897d5edcb'></a>

CAPTION ERROR

<a id='c542346b-14ad-4132-a91b-870e05c82ccb'></a>

CAPTION ERROR

<a id='88bee92a-be09-473b-84ac-01fb94ed97e5'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
<::figure
: diagram::>
Figure 2. Setup for use of a 1.2-micron administration of dextrose-amino admixture with lipid injectable emulsion given as a separate infusion. PN, parenteral nutrition.

The diagram illustrates a medical setup for administering parenteral nutrition (PN) and lipid emulsion. Two separate bags are shown at the top. The left bag is labeled "PN" and the right bag is labeled "Lipid emulsion". Each bag is connected to a "Large volume pump" below it. The tubing from both pumps converges into a single line. This combined line then passes through a "1.2-micron filter" before connecting to a "Patient". Arrows indicate the flow of fluids from the bags, through the pumps and filter, to the patient.
<::
ENCE AND
ICAL NUTRITION
Enteral Nutrition

<a id='a6626361-dc58-4564-a4de-f8bb66da42b8'></a>

CAPTION ERROR

<a id='45557744-53ed-4e53-889e-e2d37ce23797'></a>

Electrolytes
<table id="17-1">
<tr><td id="17-2">Electrolyte</td><td id="17-3">Maintenance</td><td id="17-4">Intake Maximum</td></tr>
<tr><td id="17-5">Sodium</td><td id="17-6">1 – 2 mEq/kg/day</td><td id="17-7">150 mEq/L (NS concentration)</td></tr>
<tr><td id="17-8">Potassium</td><td id="17-9">1 – 2 mEq/kg/day</td><td id="17-a">240 mEq/day</td></tr>
<tr><td id="17-b">Calcium</td><td id="17-c">10 – 15 mEq/day</td><td id="17-d">25 mEq/day</td></tr>
<tr><td id="17-e">Magnesium</td><td id="17-f">8 – 20 mEq/day</td><td id="17-g">48 mEq/day</td></tr>
<tr><td id="17-h">Phosphate</td><td id="17-i">20 - 40 mmol/day</td><td id="17-j">60 mmol/day</td></tr>
<tr><td id="17-k">Chloride/acetate</td><td id="17-l" colspan="2">Adjust salts to maintain acid base balance</td></tr>
</table>
© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
Derenski K, et al. Parenteral Nutrition Basics for the Clinician Caring for the Adult Patient, NCP epub July 2016

<a id='bb97700a-c749-46aa-abf8-88da9eb18b57'></a>

spen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='ab9377a7-079c-490d-bb2f-32e3fe25d7be'></a>

CAPTION ERROR

<a id='df681f83-9833-40cf-a944-2fb26c92e2ff'></a>

CAPTION ERROR

<a id='2e77fe00-abca-45ab-9102-099ef0672599'></a>

18

<a id='0cf093df-d44e-41e0-a013-c2c08913bcd8'></a>

CAPTION ERROR

<a id='5e0f5ea8-f707-49bf-bea9-9ae789c350c9'></a>

Electrolytes
<table id="18-1">
<tr><td id="18-2">Electrolyte</td><td id="18-3">Salt</td></tr>
<tr><td id="18-4">Sodium</td><td id="18-5">Chloride, acetate, phosphate</td></tr>
<tr><td id="18-6">Potassium</td><td id="18-7">Chloride, acetate, phosphate</td></tr>
<tr><td id="18-8">Chloride</td><td id="18-9">Sodium, potassium</td></tr>
<tr><td id="18-a">Acetate</td><td id="18-b">Sodium, potassium</td></tr>
<tr><td id="18-c">Calcium</td><td id="18-d">Gluconate</td></tr>
<tr><td id="18-e">Magnesium</td><td id="18-f">Sulfate</td></tr>
</table>
* Magnesium Sulfate and Calcium Gluconate are the preferred salts in PN
* 3 mmol of sodium phosphate = 4 mEq sodium
* 3 mmol of potassium phosphate = 4.4 mEq potassium

<a id='544f7078-3585-4c10-97aa-d664ba46a78d'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='9af3c8b6-5222-4ae9-932d-69d26d312a75'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='054f6741-c0ad-4c96-8352-57ff7f03c2a1'></a>

23

<a id='39db24fe-5f0b-4d4a-a64d-1e929a0f0e52'></a>

Vitamins
MVI-13 10 mL provides the following
<table id="18-g">
<tr><td id="18-h">Ascorbic acid</td><td id="18-i">200 mg</td><td id="18-j">Pyridoxine (B6)</td><td id="18-k">6 mg</td></tr>
<tr><td id="18-l">Vitamin A</td><td id="18-m">3300 IU</td><td id="18-n">Biotin (B7)</td><td id="18-o">60 mcg</td></tr>
<tr><td id="18-p">Vitamin D3</td><td id="18-q">200 IU</td><td id="18-r">Cyanocobalamin (B12)</td><td id="18-s">5 mcg</td></tr>
<tr><td id="18-t">Thiamin (B1)</td><td id="18-u">6 mg</td><td id="18-v">Vitamin E</td><td id="18-w">10 IU</td></tr>
<tr><td id="18-x">Riboflavin (B2)</td><td id="18-y">3.6 mg</td><td id="18-z">Vitamin K</td><td id="18-A">150 mcg</td></tr>
<tr><td id="18-B">Niacinamide (B3)</td><td id="18-C">40 mg</td><td id="18-D">Folic acid</td><td id="18-E">600 mcg</td></tr>
<tr><td id="18-F">Dexpanthenol (B5)</td><td id="18-G">15 mg</td><td id="18-H"></td><td id="18-I"></td></tr>
</table>

<a id='f093e6d4-df10-4f67-b4d8-0a7782a628dc'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='061495f4-41d3-4b1c-bba7-f058d5a9e452'></a>

CAPTION ERROR

<a id='ac6f0865-dcda-4b13-b732-4fef2cd7d2e5'></a>

CAPTION ERROR

<a id='639a299b-57aa-4086-8f6a-1dfa304ed520'></a>

CAPTION ERROR

<a id='429eb236-9b15-42a4-9d1a-2656f459177f'></a>

CAPTION ERROR

<a id='14dc4f59-6c1f-4f26-8b01-70bb2caae104'></a>

# Trace Elements
<table id="19-1">
<tr><td id="19-2">Trace Element</td><td id="19-3">Deficiency</td></tr>
<tr><td id="19-4">Zinc</td><td id="19-5">Dermatitis, alopecia, growth retardation, diarrhea</td></tr>
<tr><td id="19-6">Copper</td><td id="19-7">Anemia, depigmentation of hair, neurologic abnormalities</td></tr>
<tr><td id="19-8">Chromium</td><td id="19-9">Glucose intolerance</td></tr>
<tr><td id="19-a">Manganese</td><td id="19-b">Not well documented</td></tr>
<tr><td id="19-c">Selenium</td><td id="19-d">Cardiomyopathy</td></tr>
</table>

<a id='bd50ce0f-403b-4df2-9a1c-638d0a3cf2bd'></a>

- Tralament™ contains:
  Zinc 3 mg
  Copper 0.3 mg
  Manganese 55 mcg
  Selenium 60 mcg

<a id='c14339f6-8dd1-4350-9502-75a11dcc7c67'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='ce79b0c4-b5f8-48f6-abe2-4202c4174677'></a>

CAPTION ERROR

<a id='36e37d1f-174f-4184-8194-037d25f3eda0'></a>

Trace Elements

- Check for availability of single entity TE
- Zinc
  * Consider additional 10-15 mg/daily
  * High GI loss, decubitus ulcers
- Copper
  * Eliminated exclusively through bile
  * Hold or decrease in cholestasis
- Chromium
  * Renally eliminated
  * Consider holding or decreasing in renal failure
- Manganese
  * Eliminated exclusively through bile
  * Hold or decrease in cholestasis
- Selenium
  * Consider additional 20-40 mcg/daily
  * Burns, malabsorptive states, critically ill

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='29e03f7b-fdc7-4fed-8069-a8d296d479f6'></a>

spen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='ef100562-158f-4ae4-b856-1bfdcf34c8fc'></a>

26

<a id='6ae428a1-179f-4638-8fc3-48ca9ba43c86'></a>

20

<a id='27b58db5-d575-4b1e-9d97-bcfe7868983d'></a>

CAPTION ERROR

<a id='2ead25b0-25cf-410f-875e-44d164c79fdb'></a>

©2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='e698eb47-363d-405f-87f0-c247d48f2a16'></a>

8/5/2025

<a id='8a6d5cdd-741f-4818-8a9e-d4a891f0123b'></a>

# PN Osmolarity

*   Provides limits for safe administration of peripheral PN
    *   Peripheral < 900 mOsm/L
    *   Central > 900 mOsm/L

©2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='b50c5d5b-a887-4633-a042-85762517ccc9'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='e897bc4e-f91c-403c-8a56-b63ed921b468'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='2200b678-da71-45e7-9933-bde480ac03c5'></a>

CAPTION ERROR

<a id='d1f0ea23-0450-4494-bbae-527b6fce527d'></a>

PN Osmolarity

<table id="20-1">
<tr><td id="20-2">PN Component</td><td id="20-3">mOsm</td></tr>
<tr><td id="20-4">Amino Acids</td><td id="20-5">1 g = 10 mOsm</td></tr>
<tr><td id="20-6">Dextrose</td><td id="20-7">1 g = 5 mOsm</td></tr>
<tr><td id="20-8">IV Lipid Emulsion</td><td id="20-9">1 g = 0.71 mOsm</td></tr>
<tr><td id="20-a">Electrolytes</td><td id="20-b">1 mEq = 1 mOsm</td></tr>
</table>

* REMEMBER this is an estimate base on the osmolarity of the PN components
* ILE osmolarity is product dependent

<a id='cbf74219-55fc-4e30-9e45-cf3094f43a0a'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='8faa48fa-3148-49e8-a7ea-f176532d7a03'></a>

CAPTION ERROR

<a id='3c9ba264-0b59-445a-a3ed-9c97d335cd19'></a>

21

<a id='be67417c-f205-4ca9-b01c-6a01f8e03198'></a>

14

<a id='cad0488f-00d2-4e8a-990c-0ccd9c1e3b7a'></a>

8/5/2025

<a id='b0a9e46e-d8d3-47be-9fb7-fe1edbb0e7e0'></a>

# Question 1

1 L PN is compounded with the following content:
- Amino acid - 60 g
- Dextrose - 170 g
- 20% ILE - 20 g
- Electrolytes - 243 mEq

What is the estimated osmolarity?
a) 1607 mOsm/L
b) 1707 mOsm/L
c) 1807 mOsm/L
d) 1907 mOsm/L

<a id='ca2b032c-f088-4b4c-a9d2-3aaa2bf75079'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='4429eebf-fcc8-420c-b123-f1248930dd54'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='487cba00-178a-4d90-8265-b5113be93116'></a>

CAPTION ERROR

<a id='4708caec-950c-4e83-badb-78c27c603141'></a>

## Question 1

Answer b) 1707 mOsm/L

Amino acid 60g × 10 mOsm/g = 600 mOsm

Dextrose 170g × 5 mOsm/g = 850 mOsm

ILE 20g × 0.71 mOsm/g = 14.2 mOsm

Electrolytes 243 mEq × 1 mOsm/mEq = 243 mOsm

600 mOsm + 850 mOsm + 14.2 mOsm + 243 mOsm = 1707.2 mOsm/L

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='e94f5932-e197-4113-821a-08fee5ff0643'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='7561a335-dfb6-4f6f-90a9-a70862a9bf1f'></a>

CAPTION ERROR

<a id='694c6ec3-c162-44d7-8e3c-ee5ebdc1a4a0'></a>

CAPTION ERROR

<a id='ded7e385-a5c1-48b0-8fc6-ebe410fe0e0d'></a>

CAPTION ERROR

<a id='672be30b-6682-49cd-808c-31363694d9f7'></a>

CAPTION ERROR

<a id='2c66cca5-034c-42da-8dfe-b88dc04256cc'></a>

# Initiating PN

*   Dextrose
    *   Provides ~50% of total calorie intake or 60 – 85% of NPC
    *   Most PN will have goal doses of 150 – 350 g/day
    *   Initiate at roughly ½ of goal dextrose
        *   150 – 200 g/day (general population)
        *   100 – 150 g/day (h/o DM or stress hyperglycemia)
    *   Advance to goal when BG controlled and electrolytes and acid base status stabilized
    *   Optimal glucose infusion rate 3 – 5 mg/kg/min (stressed, hospitalized)
        *   Reserve 6 mg/kg/min in non-stressed, looking for weight gain
        *   Maximum 7 g/kg/day

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='1076ec11-4f41-4f6d-8338-b0e37f0511a0'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='5496b3ea-3e78-46a7-a04a-3259de004ecd'></a>

31

<a id='05a8935f-a610-4276-ad9d-3d7f16f58aba'></a>

## Initiating PN

*   Protein
    *   Minimal metabolic effects
    *   Can initiate at goal
    *   Caution with azotemia (BUN > 100 mg/dL)

*   Fat (ILE)
    *   15 – 30% total calories
    *   Can estimate dose based on body weight
        *   <1-2g/kg/day
    *   Do not exceed 2.5 g/kg/day
    *   To prevent EFAD (100 g weekly SO-ILE)
        *   Give 20% ILE 250 mL twice weekly or 500 mL weekly
        *   This is important during shortages

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='a0a763a6-f8f0-45a5-b80b-7d4ccaef2d86'></a>

uspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='c7777ab9-479e-46ff-8282-6603c8ba0e6a'></a>

CAPTION ERROR

<a id='e56f8095-0e6d-440b-ade4-13eae25e01fb'></a>

23

<a id='fa887af3-8794-4113-87b3-9c38b195bbd9'></a>

CAPTION ERROR

<a id='519d237d-807a-4b52-830b-7caf5655b4c3'></a>

CAPTION ERROR

<a id='64738b97-c45f-4f9c-87ac-5d3d36d1ad81'></a>

Question 2

A 3-in-1 TPN is compounded with the following:

- 440 mL of 15% Clinisol®
- 340 mL of 70% Dextrose
- 100 mL of 20% ILE

How much protein is provided per day?

a) 60 grams/day: [ ]
b) 66 grams/day: [ ]
c) 70 grams/day: [ ]
d) 76 grams/day: [ ]

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='c524ac08-0c54-4415-9736-79d48bfbadd2'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='092c7697-2a0e-4d9c-8054-41f00e9899e6'></a>

CAPTION ERROR

<a id='290c9d87-12b0-4556-ba2f-552e2c6f8455'></a>

Question 2

Answer b) 66 grams

$\frac{15g}{100mL} = \frac{x (g)}{440mL}$

$100x = 15 \times 440$

$x = \frac{6600}{100}$

$x = 66 \text{ grams}$

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='5c9bb804-02f4-4727-abce-079f429ed2db'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='66dfc63b-e3ab-420e-81aa-8f4bb97c4fef'></a>

CAPTION ERROR

<a id='f4695d4b-7ec8-4720-a1b6-f1099ad1f31b'></a>

CAPTION ERROR

<a id='0cdb0d6d-7471-474e-8edb-b74e861699cf'></a>

17

<a id='cb83486d-8a6f-48a1-b048-bb50fdd30f33'></a>

CAPTION ERROR

<a id='edd5b51c-8a31-4b7e-9e36-79ccc415a7d2'></a>

## Question 3

A 3-in-1 TPN is compounded with the following:
- 440 mL of 15% Clinisol
- 340 mL of 70% Dextrose
- 100 mL of 20% ILE

How many total calories are provided per day?
a) 1153 kcal
b) 1173 kcal
c) 1273 kcal
d) 1373 kcal

<a id='23c2059f-1733-44e5-9760-bdaf8ee2a767'></a>

aspen

LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='4b015a52-2cf2-4ae9-9669-ecafe05f3d31'></a>

CAPTION ERROR

<a id='cb3b67d0-5750-475d-b838-11672a25e189'></a>

Question 3

Answer c) 1273 kcal

66 grams Protein × 4kcal/gram = 264 kcal

70g dexrose = x (g dextrose)
---
100mL 340mL

100x = 23800
x = 238 g dextrose
238 g dextrose × 3.4kcal/gram = 809 kcal

100 mL ILE × 2kcal/mL = 200 kcal

264 protein kcal + 809 dextrose kcal + 200 ILE kcal = 1273 total daily kcal

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
36

<a id='e63d7ec5-cf81-44c7-afe7-dcec36b9ea1b'></a>

spen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='1a0dea5b-ef77-449b-8475-2fc82cb93051'></a>

CAPTION ERROR

<a id='0d5e6cbb-8459-4aba-b13a-489dddd536cb'></a>

CAPTION ERROR

<a id='df00c5e1-f04d-45ec-b208-c21ffc690c64'></a>

ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='23fd5579-c32b-4707-b2c5-942facdb5609'></a>

CAPTION ERROR

<a id='70d5ff6c-028c-4070-891e-34c75045f91a'></a>

CAPTION ERROR

<a id='20e8f89a-f799-4c32-94cc-44ac8ac7d6bc'></a>

# PN Administration

*   Initial PN is infused 24 hour (continuous)
*   When plans move to long term PN cycling is a possibility
    *   8 – 22 hour infusion
    *   PN is “cycled down” based on tolerance
    *   PN is titrated and tapered over 1 – 2 hours before and after infusion
        *   “ramp up and down”
        *   Prevents hyper- and hypoglycemia
    *   Cycling improves QOL
    *   May alleviate PNALD

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='4a449f60-5530-41e0-a11d-b6e10547ab10'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='dc53e309-21da-4703-aa05-a1a2f1209d43'></a>

CAPTION ERROR

<a id='59e5864b-e336-4ab0-ad27-ef09f34f12c5'></a>

Monitoring

*   Fluid balance
    *   Daily weights, I/Os
*   Acid-base status
*   Visceral proteins?
*   C-reactive protein
    *   APR that marks inflammation

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='24d4e0c0-b8f1-433b-9469-833e1a816c0f'></a>

spen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='ccfbf6e9-6158-4205-b278-be023350777e'></a>

38

<a id='fc47b264-4d6f-41f3-895f-a592b3d5d179'></a>

26

<a id='6b4b5616-3c3f-45bd-a520-9b3df99c819d'></a>

CAPTION ERROR

<a id='db4abb02-9d62-498b-abc8-588ec219c267'></a>

CAPTION ERROR

<a id='cc784ed3-18c6-4759-a889-365cc468f3d8'></a>

Position Paper

---

<::transcription of the content
: figure::>
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition
<::>

<a id='d1b14462-83ca-4e58-8360-0c1f52f4f3ea'></a>

PODCAST

The Use of Visceral Proteins as Nutrition Markers: An
ASPEN Position Paper

<a id='e76d2eb3-8480-463b-9ddd-9adf503414ca'></a>

Nutrition in Clinical Practice
Volume 36 Number 1
February 2021 22-28
© 2020 American Society for
Parenteral and Enteral Nutrition
DOI: 10.1002/ncp.10588
wileyonlinelibrary.com
WILEY

<a id='e362805d-7223-43bb-9c2a-9ef302686cd3'></a>

David C. Evans, MD, FACS, PNS¹; Mark R. Corkins, MD, CNSC, FASPEN, AGAF,
FAAP²; Ainsley Malone, MS, RD, LD, CNSC, FAND, FASPEN³,⁴④;
Sarah Miller, PharmD, BCNSP⁵; Kris M. Mogensen, MS, RD-AP, LDN, CNSC⁶④;
Peggi Guenter, PhD, RN, FAAN, FASPEN⁷④; Gordon L. Jensen, MD, PhD⁸;
and the ASPEN Malnutrition Committee⁴

<a id='e358f339-a642-4ec6-8668-f0aeceb4c257'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='2b219033-49fc-4da7-883c-c3df34029bd3'></a>

39

<a id='24b57307-425c-450d-9f6b-f04cb49575fe'></a>

Executive Summary

*   Serum albumin and prealbumin are not components of currently accepted definitions of malnutrition.
*   Serum albumin and prealbumin do not serve as valid proxy measures of total body protein or total muscle mass and should not be used as nutrition markers.
*   The serum concentrations of albumin and prealbumin decline in the presence of inflammation, regardless of underlying nutrition status.
*   Serum albumin and prealbumin declines must be recognized as inflammatory markers associated with "nutrition risk" in the context of nutrition assessment rather than with malnutrition per se. Nutrition risk is broadly defined as the risk of developing malnutrition and/or poor clinical outcomes if nutrition support is not provided.
*   The role of serum albumin and prealbumin in monitoring delivery and efficacy of nutrition support remains undefined. Their normalization may indicate the resolution of inflammation, the reduction of nutrition risk, a transition to anabolism, or potentially lower calorie and protein requirements.

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

Nutr Clin Pract. 2021:36:22–28

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='9b73401c-d58a-4802-b88a-01d6425eb10b'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='845220b3-9e8d-40de-8b30-63afb694ea6f'></a>

40

<a id='54df9484-5248-4c6a-8fce-d26093cddfd8'></a>

20

<a id='cb53c993-00d0-45f4-bf7e-867b64db2df5'></a>

CAPTION ERROR

<a id='3c910d5e-fd79-4bbe-9cdb-dd55b670bdff'></a>

&#169; 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='6981a1bc-ee0b-4a0d-94d6-5d6e2bc06d97'></a>

CAPTION ERROR

<a id='d4011d79-6d30-4a84-b1e2-7da72d005612'></a>

Monitoring

*   Nitrogen balance
    *   Asses protein requirement and adequacy
    *   Stool and skin losses are estimated to be 2 g nitrogen/day

nitrogen balance = nitrogen intake - nitrogen output

nitrogen balance (g/day) = (protein intake / 6.25) - (urinary nitrogen + losses)

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='bca7787d-2d65-4c1b-9b08-8ae6b78cc5fd'></a>

<::transcription of the content
: aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition::>

<a id='86e1a55d-21f3-425d-8f65-8e24a579f11d'></a>

41

<a id='01c356c4-57ad-43ed-a5f6-1faa7ebb0ca1'></a>

Monitoring
* Indirect calorimetry
  - RQ is the ratio of CO₂ production to O₂ consumption

<table id="27-1">
<tr><td id="27-2">Substrate Utilization</td><td id="27-3">RQ</td></tr>
<tr><td id="27-4">Ethanol</td><td id="27-5">0.67</td></tr>
<tr><td id="27-6">Fat oxidation</td><td id="27-7">0.71</td></tr>
<tr><td id="27-8">Protein oxidation</td><td id="27-9">0.82</td></tr>
<tr><td id="27-a">Mixed substrate oxidation</td><td id="27-b">0.85</td></tr>
<tr><td id="27-c">Carbohydrate oxidation</td><td id="27-d">1</td></tr>
<tr><td id="27-e">Lipogenesis</td><td id="27-f">1-1.2</td></tr>
</table>

<a id='5781597e-f662-48d0-97b7-66e4e0d6c480'></a>

spen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='e3e1f632-0142-436f-8d83-d41b52d23a3b'></a>

CAPTION ERROR

<a id='376d6417-a382-4b7e-a8c3-41a9e43803dd'></a>

28

<a id='99c02409-a6e5-4095-b0cd-ea5b12e9a0be'></a>

CAPTION ERROR

<a id='ba45d487-c0a5-40a5-8857-b7be54c561ee'></a>

CAPTION ERROR

<a id='44b9dd59-2a6d-4ae7-aecf-e394dfb7a4b3'></a>

Laboratory Monitoring
<table id="28-1">
<tr><td id="28-2">Laboratory</td><td id="28-3">Baseline</td><td id="28-4">Initiation</td><td id="28-5">Critically Ill</td><td id="28-6">Stable Inpatient</td><td id="28-7">Stable Home</td></tr>
<tr><td id="28-8">Serum chemistry</td><td id="28-9">✔</td><td id="28-a">Daily x 7 days</td><td id="28-b">Daily</td><td id="28-c">1 – 3 times per week</td><td id="28-d">Every other week for 1 – 3 months then monthly</td></tr>
<tr><td id="28-e">Liver function tests</td><td id="28-f">✔</td><td id="28-g"></td><td id="28-h">Weekly</td><td id="28-i">Monthly</td><td id="28-j">Same as above</td></tr>
<tr><td id="28-k">CBC with differential</td><td id="28-l">✔</td><td id="28-m"></td><td id="28-n">Weekly</td><td id="28-o">Weekly</td><td id="28-p">As needed</td></tr>
</table>
* Chemistry – electrolytes, BUN, SCr, glucose
  – Corrected Ca++ = Serum Ca + [0.8 x (4 – serum albumin)]
* LFT – AST, ALT, total bilirubin, Alk Phos
Derenski K, et al. Parenteral Nutrition Basics for the Clinician Caring for the Adult Patient, NCP epub July 2016

<a id='6b12a621-7746-4eb3-ab17-dfb17fedebb2'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='c0db4f71-5b9f-4d9f-8625-b09bee77180b'></a>

CAPTION ERROR

<a id='dae9e5a3-b6b9-4b26-acb3-3f0bf916656d'></a>

Laboratory Monitoring
<table id="28-q">
<tr><td id="28-r">Laboratory</td><td id="28-s">Baseline</td><td id="28-t">Initiation</td><td id="28-u">Critically Ill</td><td id="28-v">Stable Inpatient</td><td id="28-w">Stable Home</td></tr>
<tr><td id="28-x">Triglycerides</td><td id="28-y">✔</td><td id="28-z"></td><td id="28-A">Weekly</td><td id="28-B">Weekly</td><td id="28-C">Every other week for 1-3 months then monthly</td></tr>
<tr><td id="28-D">Capillary glucose</td><td id="28-E"></td><td id="28-F">Every 6 hours</td><td id="28-G">Every 4-6 hours</td><td id="28-H">Every 6 hours</td><td id="28-I">As needed</td></tr>
<tr><td id="28-J">CBC with differential</td><td id="28-K">✔</td><td id="28-L"></td><td id="28-M">Weekly</td><td id="28-N">Weekly</td><td id="28-O">As needed</td></tr>
</table>
* Target BG 140 – 180 mg/dL
* Can adjust POCT BG based on trends and h/o DM

<a id='a4835144-e051-4d78-bfc5-f6be0d2dac0e'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='59908faf-1160-4174-a3c4-ae760f08fc60'></a>

44

<a id='b1aa7f5e-3d1d-4ec7-8e1c-50a7afba4d27'></a>

CAPTION ERROR

<a id='a13a2099-2fb7-42e9-8ec9-03b2092aea54'></a>

22

<a id='cfeef2b8-37ca-42a6-86bd-d4ab9b278f74'></a>

CAPTION ERROR

<a id='bdaa8f05-18f4-4937-8053-aff1d47f4c43'></a>

PN Complications

*   Mechanical
    *   CVC, occlusion, phlebitis, pump failure
*   Infectious
    *   PN contamination, bacteremia, site infection
*   Metabolic
    *   Glycemic control
    *   Fluids and electrolytes, acid-base balance
    *   Renal and hepatic issues
    *   Nutrient excess or deficiency
    *   Bone diseases

©2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='897e09a9-8b14-4315-bcc2-67eb09233832'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='0b7387ac-5127-4000-83d7-c268959d9cde'></a>

CAPTION ERROR

<a id='e8be2a1a-2e0c-411a-8a68-21cd303e8746'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

Catheter Issues

*   Patency
    *   Ability to infuse or aspirate without resistance
*   Thrombotic
    *   Intraluminal occlusion or fibrin sleeve
        *   Ensure adequate flushing
        *   Instill anti-thrombotic therapy
    *   Vessel thrombosis
        *   Evaluate for systemic anticoagulation
    *   Can be linked to increased infection risk
    *   Fibrin sheaths promote bacterial adhesion

<::Four circular diagrams illustrating different types of catheter issues:
1.  A cross-section of a catheter with an intraluminal thrombus.
    Label: Intraluminal thrombus
2.  A cross-section of a catheter with a fibrin tail.
    Label: Fibrin tail
3.  A cross-section of a catheter with a mural thrombus.
    Label: Mural thrombus
4.  A cross-section of a catheter with a fibrin sheath.
    Label: Fibrin sheath
: diagram::>

<::Logo: aspen
Text: LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION American Society for Parenteral and Enteral Nutrition
: logo::>

<a id='fe283788-0ec6-4303-b155-76617ea5a4fe'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='5148c6fb-91e6-4f03-a22b-6410a7853850'></a>

CAPTION ERROR

<a id='37c5f3e3-f919-42eb-ab7e-0cc7354bc561'></a>

30

<a id='d1ff82bc-218b-472a-91fc-2d9de3d9f89d'></a>

23

<a id='70675e37-4b05-4205-8b55-2c3989c3f47a'></a>

CAPTION ERROR

<a id='e55ffc45-08ee-4883-a67f-f415d95f7275'></a>

# Catheter Issues

Non-thrombotic
- Mechanical occlusion – kinking of CVC, pinch-off syndrome
- PN related
  - Calcium-phosphate – infuse acidic agent 0.1 N HCl acid
  - Lipid deposit – infuse ethanol 70%
- Drug related
  - Acid soluble – 0.1 Normal HCl acid (eg. vancomycin)
  - Base soluble – sodium bicarbonate 8.4% (eg. phenytoin)

<a id='bd665b0e-fe09-4ff2-90a6-28b8623e6803'></a>

<::An image displaying four circular diagrams, each illustrating a different type of thrombus or fibrin formation within a vessel. From left to right:
1.  **Intraluminal thrombus**: A diagram showing a vessel with a small, red, granular mass located inside the lumen.
2.  **Fibrin tail**: A diagram showing a vessel with a larger, elongated, red, granular mass extending from the vessel opening, resembling a tail.
3.  **Mural thrombus**: A diagram showing a vessel with a large, irregular, red, granular mass adhering to the inner wall of the vessel, partially obstructing the lumen.
4.  **Fibrin sheath**: A diagram showing a vessel with a thick, red, granular layer completely encasing the outside of the vessel opening, forming a sheath.
: diagram::>

<a id='37bf8838-9b37-4013-92bd-4be2ae03fe2c'></a>

aspen

LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='1b69e2bd-5b63-4737-8b6a-9f934d20c977'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='b43aae5e-5427-49f6-99dc-23bfb0e6a96f'></a>

CAPTION ERROR

<a id='b1b55c8f-0837-4e11-b75c-7c14b590a228'></a>

Glycemic Control

*   Target BG – 140 – 180 mg/dL
*   Initiate PN @ 50% of target dextrose
*   Remove dextrose from maintenance IVF
*   Pharmacotherapy
    *   Regular insulin added to PN (0.1 units/g dextrose)
    *   Regular correctional ISS (q6h to q4h)
    *   Review response to correctional and add back to next PN
    *   Regular insulin infusion (preferred in critically ill)
*   Modify calories
    *   Increase fat calories and decrease dextrose calories
    *   Reassess patient for caloric needs

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='db8615e0-b516-45a7-a29a-71a3736b6eac'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='65177dff-e447-4849-85ab-981ee6608801'></a>

CAPTION ERROR

<a id='4c6dc04f-d29e-47b6-96da-01dc06211064'></a>

31

<a id='260ea9a7-34f6-4d62-8148-b2a71fe7b43e'></a>

24

<a id='ff01dfa7-4835-49bf-9c4d-b5c300f3ba42'></a>

8/5/2025

<a id='58ab22ee-34fd-4c9d-ac9c-1e93a9245925'></a>

Refeeding Syndrome

* Can occur with any dextrose source
  * PN, EN, PO, dextrose containing base fluid
* Carbohydrate introduction causes
  * Insulin secretion
  * Electrolyte shifting
  * Thiamine depletion
* At risk patients
  * Anorexia, alcoholism, chronic diseases associated with malnutrition
* Correct electrolyte derangements
* Add Thiamine 100 mg daily for 5 – 10 days

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='56924049-d3d5-4a89-b55c-7d13fbe13a8d'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='343ef80b-8d6a-4a33-93e0-56e5665286e5'></a>

CAPTION ERROR

<a id='295a7fec-dba6-4360-b9a8-4a3d0616d3bc'></a>

Consensus Recommendation

# ASPEN Consensus Recommendations for Refeeding Syndrome

Joshua S. V. da Silva, DO¹; David S. Seres, MD, ScM, PNS, FASPEN²;
Kim Sabino, MS, RD, CNSC³; Stephen C. Adams, MS, RPh, BCNSP⁴;
Gideon J. Berdahl, BSFNS, BSPS⁵; Sandra Wolfe Citty, PhD, APRN-BC, CNE⁶;
M. Petrea Cober, PharmD, BCNSP, BCPPS, FASPEN⁷,⁸; David C. Evans, MD,
FACS⁹; June R. Greaves, RD, CNSC, CDN, LD, LDN¹⁰;
Kathleen M. Gura, PharmD, BCNSP, FASHP, FPPPG, FASPEN¹¹;
Austin Michalski, RDN, CNSC¹²; Stephen Plogsted, BS, PharmD, BCNSP, CNSC¹³;
Gordon S. Sacks, PharmD, BCNSP, FASPEN, FCCP¹⁴; Anne M. Tucker, PharmD,
BCNSP¹⁵; Patricia Worthington, MSN, RN, CNSC¹⁶; Renee N. Walker, MS, RDN,
LD, CNSC, FAND¹⁷; Phil Ayers, PharmD, BCNSP, FMSHP, FASHP¹⁸;
and Parenteral Nutrition Safety and Clinical Practice Committees, American Society
for Parenteral and Enteral Nutrition

<::attestation: official_logo
[Readable Text if any: aspen LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION American Society for Parenteral and Enteral Nutrition]
[Short description of visual elements and positioning: Top right corner, black and white logo with text]::>

Nutrition in Clinical Practice
Volume 35 Number 2
April 2020 178-195
© 2020 American Society for
Parenteral and Enteral Nutritio
DOI: 10.1002/ncp.10474
wileyonlinelibrary.com

WILEY

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<::attestation: official_logo
[Readable Text if any: aspen LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION American Society for Parenteral and Enteral Nutrition]
[Short description of visual elements and positioning: Bottom right corner, black and white logo with text]::>

<a id='dc7648d4-2bd8-4aa4-8cb9-40c7b1648c0b'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='0f907864-7336-4acd-88cb-5b734ecaaa40'></a>

32

<a id='4f1cdb5e-0691-4445-bd57-aaffd7a8f892'></a>

CAPTION ERROR

<a id='9c8a286d-a0e4-4b9f-9ae6-0ad7224dd105'></a>

50

<a id='fbc6e785-0126-44df-996e-5f7fa96fff40'></a>

CAPTION ERROR

<a id='4efb7f41-ed58-4004-9bf5-449b8c3e39eb'></a>

ASPEN Consensus Criteria for Identifying at Risk Patients
<table id="32-1">
<tr><td id="32-2" colspan="3">Table 3. ASPEN Consensus Criteria for Identifying Adult Patients at Risk for Refeeding Syndrome.49,71,110</td></tr>
<tr><td id="32-3"></td><td id="32-4">Moderate Risk: 2 Risk Criteria Needed</td><td id="32-5">Significant Risk: 1 Risk Criterion Needed</td></tr>
<tr><td id="32-6">BMI</td><td id="32-7">16-18.5 kg/m</td><td id="32-8"><16 kg/m</td></tr>
<tr><td id="32-9">Weight loss</td><td id="32-a">5% in 1 month</td><td id="32-b">7.5% in 3 months or >10% in 6 months</td></tr>
<tr><td id="32-c">Caloric intake</td><td id="32-d">None or negligible oral intake for 5-6 days OR <75% of estimated energy requirement for >7 days during an acute illness or injury OR <75% of estimated energy requirement for >1 month</td><td id="32-e">None or negligible oral intake for >7 days OR <50% of estimated energy requirement for >5 days during an acute illness or injury OR <50% of estimated energy requirement for >1 month</td></tr>
<tr><td id="32-f">Abnormal prefeeding potassium, phosphorus, or magnesium serum concentrations</td><td id="32-g">Minimally low levels or normal current levels with recent low levels necessitating minimal or single-dose supplementation</td><td id="32-h">Moderately/significantly low levels or minimally low/normal levels with recent low levels necessitating significant or multiple-dose supplementation</td></tr>
<tr><td id="32-i">Loss of subcutaneous fat</td><td id="32-j">Evidence of moderate loss</td><td id="32-k">Evidence of severe loss</td></tr>
<tr><td id="32-l">Loss of muscle mass</td><td id="32-m">Evidence of mild or moderate loss</td><td id="32-n">Evidence of severe loss</td></tr>
<tr><td id="32-o">Higher-risk comorbidities (see Table 4)</td><td id="32-p">Moderate disease</td><td id="32-q">Severe disease</td></tr>
</table>
ASPEN, American Society for Parenteral and Enteral Nutrition; BMI, body mass index.
ªPlease note that electrolytes may be normal despite total-body deficiency, which is believed to increase risk of refeeding syndrome.

<a id='18e59324-57cb-427f-8521-034af14edc4d'></a>

(NutrClinPract.2020;35:178–195)

<a id='34a659d1-5499-41a0-9f79-ac670ea3ba22'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='49c63333-f08c-430a-85f5-e95292fdc000'></a>

CAPTION ERROR

<a id='fc6111c2-3389-4a3b-a4c2-274197af2270'></a>

Table 6. ASPEN Consensus Recommendations for Avoidance and Treatment of RS in At-Risk Adults.

<a id='7598ec66-b339-48ab-8277-c95eb53f03b4'></a>

Initiation of calories
* Initiate with 100-150 g of dextrose or 10-20 kcal/kg for the first 24 hours; advance by 33% of goal every 1 to 2 days. This includes enteral as well as parenteral glucose.
* In patients with moderate to high risk of RS with low electrolyte levels, holding the initiation or increase of calories until electrolytes are supplemented and/or normalized should be considered.
* Initiation of or increasing calories should be delayed in patients with severely low phosphorus, potassium, or magnesium levels until corrected.
* Calories from IV dextrose solutions and medications being infused in dextrose should be considered in the limits above and/or initiated with caution in patients at moderate to severe risk for RS. If a patient has received significant amounts of dextrose for several days, from maintenance IV fluids and/or medications in dextrose, and has been asymptomatic with stable electrolytes, calories from nutrition may be reintroduced at a higher amount than recommended above.

Fluid restriction
* No recommendation.

Sodium restriction
* No recommendation.

Protein restriction
* No recommendation.

Electrolytes
* Check serum potassium, magnesium, and phosphorus before initiation of nutrition.
* Monitor every 12 hours for the first 3 days in high-risk patients. May be more frequent based on clinical picture.
* Replete low electrolytes based on established standards of care.
* No recommendation can be made for whether prophylactic dosing of electrolytes should be given if prefeeding levels are normal.
* If electrolytes become difficult to correct or drop precipitously during the initiation of nutrition, decrease calories/grams of dextrose by 50% and advance the dextrose/calories by approximately 33% of goal every 1-2 days based on clinical presentation. Recommendations may be changed based on practitioner judgment and clinical presentation, and cessation of nutrition support may be considered when electrolyte levels are severely and/or life-threateningly low or dropping precipitously.

Thiamin and multivitamins
* Supplement thiamin 100 mg before feeding or before initiating dextrose-containing IV fluids in patients at risk.
* Supplement thiamin 100 mg/d for 5-7 days or longer in patients with severe starvation, chronic alcoholism, or other high risk for deficiency and/or signs of thiamin deficiency.
* Routine thiamin levels are unlikely to be of value.
* MVI is added to PN daily, unless contraindicated, as long as PN is continued. For patients receiving oral/enteral nourishment, add complete oral/enteral multivitamin once daily for 10 days or greater based on clinical status and mode of therapy.

Monitoring and long-term care
* Recommend vital signs every 4 hours for the first 24 hours after initiation of calories in patients at risk.
* Cardiorespiratory monitoring is recommended for unstable patients or those with severe deficiencies, based on established standards of care.
* Daily weights with monitored intake and output.
* Evaluate short- and long-term goals for nutrition care daily during the first several days until the patient is deemed stabilized (eg. no requirement for electrolyte supplementation for 2 days) and then based on institutional standards of care.

ASPEN, American Society for Parenteral and Enteral Nutrition; IV, intravenous; MVI, multivitamin injectable; PN, parenteral nutrition; RS, refeeding syndrome.

<a id='6395a6ff-1b00-408c-80a8-69d5d51c9c43'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='54a7c38e-855a-41a1-99aa-eaff6e5ab2d4'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

52

<a id='318ea34f-c723-4e89-9607-5ba1160ee6cd'></a>

CAPTION ERROR

<a id='4b34ff49-22b8-4f93-a7d5-85a590f5c993'></a>

33

<a id='871bfe05-294d-4c97-a307-c56362884790'></a>

26

<a id='c99f27b1-b84f-40dc-8de9-b208baf0268d'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='ec9ce8a6-d7c1-4699-9825-29874a7bd7a6'></a>

CAPTION ERROR

<a id='9588355e-1097-4e22-9611-2aadfdc2dfe8'></a>

# Hepatobiliary Complications

*   Steatosis
    *   Hepatic fat accumulation
    *   Predominantly in adults
    *   Modest elevations in transaminases within 2 weeks of PN therapy
    *   Transaminases normalize with D/C of PN
    *   Complication of overfeeding
*   Cholestasis
    *   Impaired bile secretion or biliary obstruction
    *   Elevation of alk phos, GGT, and conjugated (direct) bilirubin
    *   Elevated total bilirubin > 2 mg/dL
*   Gallbladder sludge/stones
    *   Related to lack of enteral stimulation
    *   Related to duration of PN therapy

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='af9e9bc0-3b60-4c69-a6e7-641b9427e617'></a>

aspen い
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='d6825b67-eac2-4998-87d3-2514ab6abbb1'></a>

CAPTION ERROR

<a id='3206fb21-c9d1-4428-a0cf-656fa7ced051'></a>

Hepatobiliary Complication Risk Factors

*   Energy
    *   Overfeeding promotes hepatic fat deposition
*   Carbohydrates
    *   Balanced PN formulation
*   ILE
    *   High concentrations of omega-6 fatty acids and phytosterols

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='be4c5ef4-6486-4c77-96a8-01eb194359b7'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='90a94e29-e846-4938-a8ee-07b8ea887f4c'></a>

CAPTION ERROR

<a id='1cfa23e3-d66a-46c3-a80f-ad2c2ff6bda7'></a>

CAPTION ERROR

<a id='ff4aa774-fa4a-41d6-94e5-593d85472930'></a>

CAPTION ERROR

<a id='10be28db-222d-47b4-b048-ed079d1e76ff'></a>

CAPTION ERROR

<a id='85699c32-8ad3-43cb-acd4-fff1532c6fe9'></a>

ILE and Phytosterol Content

<::bar chart: Bar chart titled "ILE and Phytosterol Content" showing Phytosterols (µg/mL) on the y-axis and different lipid emulsions on the x-axis. The y-axis ranges from 0 to 500 in increments of 50. The x-axis labels are Intralipid, 50% MCT/ 50% LCT, 80% Olive/ 20% Soybean, Smoflipid 20%, and Omegaven. The bars represent:
- Intralipid: approximately 430 µg/mL
- 50% MCT/ 50% LCT: approximately 275 µg/mL
- 80% Olive/ 20% Soybean: approximately 270 µg/mL
- Smoflipid 20%: approximately 205 µg/mL
- Omegaven: No bar is present, indicating 0 µg/mL
:chart::>

Xu Z et al. Nutrients. 2012; 4:904-21.

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='c4aeef56-a8bf-40fc-ac26-f5f5cf9973c3'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='9a5000eb-3a0f-41c1-b257-15d07eeea5aa'></a>

CAPTION ERROR

<a id='7c0d05b1-b82a-4771-be72-0b851688f2e5'></a>

Managing PN Associated Liver Complications

*   Rule out non-PN factors
    *   Medications, herbal supplements, biliary obstruction, hepatitis
*   Consider PN modifications
    *   Decrease dextrose, decrease ILE, balanced calories, cycle PN infusion
*   Maximize enteral intake
    *   Encourage oral intake if possible, slow rate EN
*   Treat SIBO
    *   Enteral antibiotics
*   Pharmacotherapy
    *   Ursodiol, antihistamines
*   Intestinal transplantation

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

56

<a id='4a7c6849-e54c-4f6d-a2c7-086550db062f'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='07310e60-81d9-40c0-a895-59832f5cc9aa'></a>

CAPTION ERROR

<a id='7f3c33a1-a696-4b32-8cb3-f1cacb7982b0'></a>

28

<a id='f0e67d15-7d8b-40b7-ad87-38138dd3d709'></a>

CAPTION ERROR

<a id='09423916-76c7-4fb1-b25e-0ec1796b3da5'></a>

## Hypertriglyceridemia

*   Can occur with dextrose overfeeding or rapid ILE administration rates
*   Review risk factors increasing intolerance
    *   Disease states, medications
*   Hold ILE if Serum TG > 400 mg/dL
*   Fat intolerant – reduce ILE
    *   < 30% of total calories or 1 g/kg/day
    *   Can administer twice weekly

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='7a32800b-a07e-4cb7-a58f-ec460a456969'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='806fe01d-ac08-4054-baa0-a3926e3ab26f'></a>

CAPTION ERROR

<a id='79e7d99b-64c6-45ba-a355-32967e2de69f'></a>

Essential Fatty Acid Deficiency (EFAD)

*   At risk patients
    *   ILE free PN > 2-4 weeks
    *   Poor nutritional status
*   Manifestations
    *   Scaly dermatitis, alopecia, poor wound healing, thrombocytopenia
    *   Triene to tetraene ratio of more than 0.2
*   How to avoid
    *   1-2% of energy should be from linoleic acid
    *   0.5% of energy should be from linolenic acid
    *   20% SO ILE 250 mL twice a week
    *   Trial topical safflower oil in those intolerant to ILE

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='5291abc1-dec2-4320-bbe6-73a1f057456d'></a>

spen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='9ec55d2c-6fc6-4f9b-9b02-aa5a1879fe8b'></a>

58

<a id='a7dbd749-2b06-4010-8b2f-c5c1c413b879'></a>

36

<a id='31fd19a0-7f09-4d29-a1dd-6a3c29e08bfe'></a>

CAPTION ERROR

<a id='ca0b25ae-82e7-418b-a498-a76f403c3393'></a>

8/5/2025

<a id='d5915219-606f-4f77-a55a-13d0a7d77c62'></a>

<table id="36-1">
<tr><td id="36-2" colspan="7">TABLE 2. CALCULATED MINIMUM ILE DAILY DOSE TO MEET 2% OF TOTAL KCAL FROM LA2-5</td></tr>
<tr><td id="36-3">Daily total caloric dose</td><td id="36-4" colspan="2">Daily dose SO-ILE (20%)</td><td id="36-5" colspan="2">Daily dose SO,MCT, OO,FO-ILE (20%)</td><td id="36-6" colspan="2">Daily dose OO, SO-ILE (20%)</td></tr>
<tr><td id="36-7">kcal</td><td id="36-8">mL*</td><td id="36-9">g</td><td id="36-a">mL*</td><td id="36-b">g</td><td id="36-c">mL*</td><td id="36-d">g</td></tr>
<tr><td id="36-e">1000</td><td id="36-f">20.4</td><td id="36-g">4.1</td><td id="36-h">62.9</td><td id="36-i">12.6</td><td id="36-j">61.5</td><td id="36-k">12.3</td></tr>
<tr><td id="36-l">1500</td><td id="36-m">30.6</td><td id="36-n">6.1</td><td id="36-o">94.3</td><td id="36-p">18.9</td><td id="36-q">92.2</td><td id="36-r">18.4</td></tr>
<tr><td id="36-s">2000</td><td id="36-t">40.8</td><td id="36-u">8.2</td><td id="36-v">125.7</td><td id="36-w">25.1</td><td id="36-x">122.9</td><td id="36-y">24.6</td></tr>
<tr><td id="36-z">Daily dose, % total kcal to meet ≥ 2% of total kcal from LA</td><td id="36-A" colspan="2">≥ 4.1%</td><td id="36-B" colspan="2">≥ 12.5%</td><td id="36-C" colspan="2">≥ 12.5%</td></tr>
</table>
Nutr Clin Pract 2020;35:769–782

<a id='77ab5198-d475-4cd0-9d00-719463dacdc9'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='643faa46-f20d-46c7-8f19-960032abef3d'></a>

CAPTION ERROR

<a id='8f35fab5-49e4-47c9-b89f-3a9c6a61c805'></a>

Metabolic Bone Disease

*   Osteoporosis
    *   Reported in 67% of long term PN due to intestinal failure
*   Osteomalacia
*   Laboratory monitoring
    *   Ca++, PTH, urine Ca++, alkaline phosphatase
*   Risk factors
    *   Malabsorptive disorders, immobility
*   Preventing and treating osteoporosis in long term PN
    *   Evaluate protein, phosphorus, calcium, sodium dosing
    *   Treat chronic metabolic acidosis
    *   Maintain Mg++ and copper intake
    *   Minimize aluminum contamination
    *   Encourage weight bearing exercise
    *   Reduce caffeine and limit alcohol intake

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='a54f3832-eabe-4b25-be8f-510edfcac5e9'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='9cc49c87-e3fa-4ab0-9806-301c30e826b2'></a>

CAPTION ERROR

<a id='70a88333-ad98-4a92-b0ef-a6a845430350'></a>

CAPTION ERROR

<a id='d236a282-7bd6-4f1e-b7bc-869dbc9f79e4'></a>

CAPTION ERROR

<a id='6b586d99-29ca-4e9c-ad4a-9de250f53ddd'></a>

Communication and Timing

<::OK, THERE IS A SMALL CHANGE...
RED BAG HAS THE SANDWICHES
GREEN BAG IS YOUR PARACHUTE
: cartoon::>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
m LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='30e757a0-9ec0-468f-a6b7-12fd05fd28cd'></a>

CAPTION ERROR

<a id='488d48d3-7fba-48f2-85af-7e1a30feee64'></a>

HPN
<::Two images showing medical equipment for home parenteral nutrition (HPN). The left image shows an open black carrying case with an infusion pump, tubing, and a fluid bag secured inside. The right image shows the inside of a backpack with an infusion pump and a fluid bag visible, suggesting portability for HPN.::>
© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
<::Logo: The ASPEN logo, featuring the word "aspen" in a stylized font, accompanied by the text "LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION" and "American Society for Parenteral and Enteral Nutrition".::>

<a id='537ede60-9145-44c3-9462-7a1a5d4debd7'></a>

CAPTION ERROR

<a id='43719bfd-efcf-4e15-92ba-6fc74181eaac'></a>

38

<a id='17071ebd-57b4-48db-b33c-5329ef84136f'></a>

CAPTION ERROR

<a id='81333481-4025-40ac-95b4-3ca564f523f1'></a>

CAPTION ERROR

<a id='6bece39f-1ec0-4e48-b69d-24ab26376347'></a>

<table id="38-1">
<tr><td id="38-2">Table 10.1. Common Indications for Home Parenteral Nutrition.2,3,6</td></tr>
<tr><td id="38-3">Short bowel syndrome</td></tr>
<tr><td id="38-4">Crohn's disease</td></tr>
<tr><td id="38-5">Intestinal motility disorders</td></tr>
<tr><td id="38-6">Chronic bowel obstruction due to benign adhesions or strictures</td></tr>
<tr><td id="38-7">Radiation enteritis</td></tr>
<tr><td id="38-8">Malabsorptive disorders</td></tr>
<tr><td id="38-9">Intestinal and pancreatic fistula</td></tr>
<tr><td id="38-a">Gastrointestinal malignancy</td></tr>
<tr><td id="38-b">Malignant bowel obstruction, carcinomatosis</td></tr>
<tr><td id="38-c">Complication of baritric sugary</td></tr>
<tr><td id="38-d">Gastroschisis</td></tr>
<tr><td id="38-e">Long-segment Hirschsprung's disease</td></tr>
</table>
Reprinted from Worthington P, Balint J, Bechtold M et al. When is parenteral nutrition appropriate?
JPEN J Parenter Enteral Nutr. 2017; 41:324-77.

<a id='014c57c8-b385-4646-82d7-a26cf890e3c8'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='c366a305-0028-401b-bd8f-88e39a348d5b'></a>

CAPTION ERROR

<a id='190a236b-7a37-41a7-9d08-93cf00440093'></a>

Medicare Coverage for Home PN

*   September 2021 new Local Coverage Determination (LCD)
*   Prosthetic Device Benefit within the Durable Medical Equipment benefit
*   PN is covered for beneficiaries who qualify under the Prosthetic Device Benefit defined in the Medicare Benefit Policy Manual, Chapter 15, Section 120

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

Practical Gastroenterology October 2021

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='ac6e0d62-3ff9-441c-9bde-ea7ae5ac141f'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='5c0fc8e3-4354-4f80-abb7-66a409a40f5f'></a>

CAPTION ERROR

<a id='81cd6662-db31-4586-a813-cec0b4ae01ae'></a>

CAPTION ERROR

<a id='98c16e18-c6eb-44ad-8417-37035d903818'></a>

32

<a id='59f5b8f3-55d0-4c62-9d84-d893f7f11b98'></a>

CAPTION ERROR

<a id='5276a1dc-cf13-4588-a5fe-312a89f6d423'></a>

Table 2. Sample Medicare PN Qualifying Checklist - PN LCD Effective September 5, 2021
<table id="39-1">
<tr><td id="39-2">Considerations</td><td id="39-3">Yes</td><td id="39-4">No</td></tr>
<tr><td id="39-5">1. Does the patient require home PN for a long and indefinite duration?</td><td id="39-6"></td><td id="39-7"></td></tr>
<tr><td id="39-8">Has this been documented clearly in the medical record by the treating practitioner prior to discharge?</td><td id="39-9"></td><td id="39-a"></td></tr>
<tr><td id="39-b">2. Daily PN is considered reasonable and necessary for a patient with severe pathology of the alimentary (GI) tract which does not allow absorption of sufficient nutrients to maintain weight and strength commensurate with the patient's general condition.</td><td id="39-c"></td><td id="39-d"></td></tr>
<tr><td id="39-e">Does the medical record provide clear documentation that supports this?</td><td id="39-f"></td><td id="39-g"></td></tr>
<tr><td id="39-h">3. Has the treating practitioner documented in the medical record that enteral nutrition has been considered and ruled out, tried and been found ineffective, or that EN exacerbates gastrointestinal tract dysfunction?</td><td id="39-i"></td><td id="39-j"></td></tr>
<tr><td id="39-k">4. Does the home PN prescription provide 20–35 calories/kg/day?</td><td id="39-l"></td><td id="39-m"></td></tr>
<tr><td id="39-n">If NO: has the treating practitioner documented in the medical record the medical necessity for a caloric intake outside this range?</td><td id="39-o"></td><td id="39-p"></td></tr>
<tr><td id="39-q">5. Does the home PN prescription provide 0.8-2.0 gm/kg/day of protein, dextrose concentration above 10%, and lipid use as prescribed in the FDA approved dosing information?</td><td id="39-r"></td><td id="39-s"></td></tr>
<tr><td id="39-t">If NO: has the treating practitioner documented the medical necessity for protein orders outside of the range of 0.8-2.0 gm/kg/day, dextrose concentration less than 10%, or lipid use outside of the FDA approved dosing information?</td><td id="39-u"></td><td id="39-v"></td></tr>
</table>

<a id='fb5bc49d-fc16-4bc5-b1d7-2495db8e9bef'></a>

CAPTION ERROR

<a id='a6019dba-8fc7-40a7-9582-be7454686c21'></a>

DOI: 10.1002/ncp.10861

CONSENSUS STATEMENT

aspen
LEARNING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION

PODCAST
Safe care transitions for patients receiving parenteral
nutrition

Stephen C. Adams MS, RPh¹ | Kathleen M. Gura PharmD² |
David S. Seres MD, ScM³ | Debbie Kovacevich RN, BSN, MPH⁴ |
Angela Maguire PharmD⁵ | Jean Herlitz RN⁶ | Todd W. Canada PharmD⁷ |
Reid Nishikawa PharmD⁸ | Joseph Boullata PharmD, RPh⁹ | and the ASPEN
Parenteral Nutrition Safety Committee

<a id='b4161988-6fb0-413d-b039-04363f54f926'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='320a6b0f-2607-4dcb-9622-b9aceda86d93'></a>

CAPTION ERROR

<a id='77398b54-fe6c-43fd-8f3d-7e33f2ce24e6'></a>

CAPTION ERROR

<a id='08504d9a-fd72-4b45-af9e-a06c49038b8e'></a>

CAPTION ERROR

<a id='9e126742-89df-40a8-9112-4b8ce5f7b355'></a>

Nutr Clin Pract. 2022;37:493-508

<a id='f3ca0182-c02f-4f29-a5f1-beaa46c93c87'></a>

 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='c3c517d0-8c5b-4b79-8f04-ef48b9cfcdad'></a>

8/5/2025

<a id='17b5bfb0-2b17-4f40-a952-fc91f55081d6'></a>

<table id="40-1">
<tr><td id="40-2"></td><td id="40-3">Day of Admission</td><td id="40-4">Subsequent days</td><td id="40-5">Day of Discharge</td><td id="40-6">Post discharge</td></tr>
<tr><td id="40-7">Indication for PN PN coverage/reimbursement is verified Patient is determined to be stable for discharge Decision to cycle PN or not is determined and communicated Patient is deemed appropriate candidate for PN Appropriate IV access is in place Goals of PN therapy is identified</td><td id="40-8"></td><td id="40-9"></td><td id="40-a"></td><td id="40-b"></td></tr>
<tr><td id="40-c">Identification of caregiver(s) Contact information for caregiver(s) is recorded Caregiver(s) is determined to be able/willing to manage PN Home environment is assessed to be safe</td><td id="40-d"></td><td id="40-e"></td><td id="40-f"></td><td id="40-g"></td></tr>
<tr><td id="40-h">PN formula and other home IV therapies PN formula is transmitted to home infusion provider, home health Orders are received for other home infusion therapies</td><td id="40-i"></td><td id="40-j"></td><td id="40-k"></td><td id="40-l"></td></tr>
<tr><td id="40-m">Medication safety Current medications are reviewed, updated, and documented Allergies are reviewed, updated and documented</td><td id="40-n"></td><td id="40-o"></td><td id="40-p"></td><td id="40-q"></td></tr>
<tr><td id="40-r">Follow up Physician/service following patient identified and documented Labs, including long-term micronutrient assessments, are ordered Discharge summary is forwarded to primary care provider Follow up appointments with following</td><td id="40-s"></td><td id="40-t"></td><td id="40-u"></td><td id="40-v"></td></tr>
</table>
Nutr Clin Pract. 2022;37:493-508

<a id='f001c50e-34e9-45ba-bda1-d62eb05c0845'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='9f311f4c-794e-4966-9678-fa0fe5f81c8a'></a>

CAPTION ERROR

<a id='3b7951ca-1b36-42c4-abe7-60fa3a1f90cf'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
<table id="40-w">
<tr><td id="40-x">Home Care / Alternate Site Care Home care infusion provider is identified Home health agency is identified Patient information is transmitted to home care infusion provider, home health agency</td><td id="40-y"></td><td id="40-z"></td><td id="40-A"></td><td id="40-B"></td></tr>
<tr><td id="40-C">Education Catheter care and management of complications are reviewed and understanding is demonstrated Details of PN administration are reviewed and understanding is demonstrated Considerations for travel while on PN are reviewed and understanding is demonstrated Monitoring complications of PN are reviewed and understanding is demonstrated Monitoring of fluid intake and losses are reviewed and understanding demonstrated</td><td id="40-D"></td><td id="40-E"></td><td id="40-F"></td><td id="40-G"></td></tr>
</table>
Nutr Clin Pract. 2022;37:493-508

<a id='ffc0513e-0b4f-44e9-ba23-f1388dae7ae6'></a>

spen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='0bbaa4e5-6cce-4c46-b4d8-318f3dc96a03'></a>

CAPTION ERROR

<a id='efb36885-d49e-4511-b268-85360c2cd785'></a>

CAPTION ERROR

<a id='b949fb07-614a-4afe-ad7f-64d4f5e23204'></a>

CAPTION ERROR

<a id='0a7c875c-2b16-4072-bb8f-aa15bb9cc114'></a>

CAPTION ERROR

<a id='6c91a88c-ae4c-4756-bbdc-464c3f9ff98a'></a>

# HPN – Facilitating Discharge

*   Obtain diagnostic testing and procedures, verify insurance
*   Establish long-term vascular access
*   Establish tolerated PN formula
*   Assess patient
    *   Activities of daily living, caregiver, home setting, determine patient buy-in
    *   Begin patient education
*   Identify outpatient management

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='4095e04f-f24f-47fb-838c-48baa24d332c'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='88b892a6-8d47-40b3-a18c-4ea9ead2e97e'></a>

CAPTION ERROR

<a id='6f9e24b1-673f-4a4b-978b-fad5a6750b09'></a>

## HPN - Home Evaluation

- Is home accessible to home health provider?
- Is environment clean with reliable utilities?
- Can patient move around home safely?
- Is the patient willing to learn operation of equipment?
- Is the caregiver willing to provide additional assistance?
- Is the patient and caregiver willing to learn problems and willing to contact appropriate services?
- Is laboratory monitoring available as needed to prevent complications?

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='a085fd53-d646-4c7a-9ab3-f4e0edc166d2'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='d98fc88e-64cc-4b54-b514-4bb4fd6d310c'></a>

CAPTION ERROR

<a id='906d1f02-ac32-4fd4-9582-63b4c05fd138'></a>

42

<a id='b90ff2c2-587d-4114-a602-dbddcb35bed4'></a>

CAPTION ERROR

<a id='7b316925-034d-4be8-bb16-38e056656e4c'></a>

CAPTION ERROR

<a id='31e4397b-b955-4b0c-b6a4-c5cbb2f668e7'></a>

Table 4.1. Clinical Conditions Warranting Cautious Initiation of
Parenteral Nutrition in Adults.⁵²,⁵³
<table id="42-1">
<tr><td id="42-2">Conditions</td><td id="42-3">Suggested Criteria</td></tr>
<tr><td id="42-4">Hyperglycemia</td><td id="42-5">Glucose greater than 180 mg/dL</td></tr>
<tr><td id="42-6">Azotemia</td><td id="42-7">Blood urea nitrogen greater than 100 mg/dL</td></tr>
<tr><td id="42-8">Hypertriglyceridemia</td><td id="42-9">Serum triglycerides greater than 200 mg/dL</td></tr>
<tr><td id="42-a">Hyponatremia</td><td id="42-b">Serum sodium less than 130 mEq/L</td></tr>
<tr><td id="42-c">Hypernatremia</td><td id="42-d">Serum sodium greater than 150 mEq/L</td></tr>
<tr><td id="42-e">Hypokalemia</td><td id="42-f">Serum potassium less than 3 mEq/L</td></tr>
<tr><td id="42-g">Hypomagnesemia</td><td id="42-h">Serum magnesium less than 1.3 mEq/L</td></tr>
<tr><td id="42-i">Hypocalcemia</td><td id="42-j">Ionized calcium less than 4.5 mg/dL</td></tr>
<tr><td id="42-k">Hypophosphatemia</td><td id="42-l">Serum phosphorus less than 2 mg/dL</td></tr>
</table>

<a id='a52743e3-204d-4919-8fa8-96f92b9e8c6a'></a>

Reprinted from Worthington P, Balint J, Bechtold M et al. When is parenteral nutrition appropriate?
*JPEN J Parenter Enteral Nutr.* 2017; 41:324-77.

<a id='9e7bd09d-32e9-499d-9dd4-2cf54c1eec94'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='4e66407c-38b9-4f31-b88e-71556ea3da20'></a>

CAPTION ERROR

<a id='dca84569-0991-45a4-8d9c-35c63537ce4b'></a>

Table 13.2. Laboratory Monitoring During PN (Adult and Pediatric).1,16,17,19
<table id="42-m">
<tr><td id="42-n"></td><td id="42-o" colspan="3">Acute Care PN</td><td id="42-p" colspan="4">Long-Term PN</td></tr>
<tr><td id="42-q">Parameter</td><td id="42-r">Baseline</td><td id="42-s">Days 1-7</td><td id="42-t">Ongoing, Stable</td><td id="42-u">Initial, Postdischarge</td><td id="42-v">Weeks 1-4 (or Until Stable)</td><td id="42-w">At 3 mo</td><td id="42-x">Ongoing, Stable</td></tr>
<tr><td id="42-y">Glucose, BUN, creatinine, electrolytes, calcium, magnesium, phosphorus</td><td id="42-z">✓</td><td id="42-A">Daily × 3 or until stable</td><td id="42-B">1-2×/wk or as clinically indicated</td><td id="42-C">✓</td><td id="42-D">(checkmark icon)</td><td id="42-E"></td><td id="42-F">Monthly</td></tr>
<tr><td id="42-G">CBC with differential</td><td id="42-H">✓</td><td id="42-I">Daily × 3 or until stable</td><td id="42-J">1-2×/wk</td><td id="42-K">✓</td><td id="42-L">(checkmark icon)</td><td id="42-M"></td><td id="42-N">Monthly</td></tr>
<tr><td id="42-O">Total bilirubin, direct bilirubin, AP, AST, ALT,</td><td id="42-P">✓</td><td id="42-Q"></td><td id="42-R">Weekly</td><td id="42-S">✓</td><td id="42-T"></td><td id="42-U"></td><td id="42-V">Monthly</td></tr>
<tr><td id="42-W">PTT, PT, INR</td><td id="42-X">✓</td><td id="42-Y"></td><td id="42-Z">Weekly</td><td id="42-10"></td><td id="42-11"></td><td id="42-12"></td><td id="42-13">Monthly</td></tr>
<tr><td id="42-14">Triglyceride level</td><td id="42-15">✓</td><td id="42-16">Pediatric: daily until stable then weekly</td><td id="42-17">Weekly</td><td id="42-18">✓</td><td id="42-19">(gray box)</td><td id="42-1a">(gray box)</td><td id="42-1b">Monthly</td></tr>
<tr><td id="42-1c">Serum proteins (to monitor inflammation)</td><td id="42-1d">✓</td><td id="42-1e"></td><td id="42-1f">Weekly</td><td id="42-1g">✓</td><td id="42-1h"></td><td id="42-1i"></td><td id="42-1j">Monthly</td></tr>
<tr><td id="42-1k">Iron indices</td><td id="42-1l"></td><td id="42-1m"></td><td id="42-1n">As clinically indicated</td><td id="42-1o"></td><td id="42-1p">(gray box)</td><td id="42-1q">✓ (gray box)</td><td id="42-1r">Every 3-6 mo</td></tr>
<tr><td id="42-1s">Zinc, selenium, manganese, copper, chromium</td><td id="42-1t"></td><td id="42-1u"></td><td id="42-1v">As clinically indicated</td><td id="42-1w"></td><td id="42-1x"></td><td id="42-1y">✓</td><td id="42-1z">Every 3-6 mo</td></tr>
<tr><td id="42-1A">Vitamin A, 25-OH vitamin D, vitamin E</td><td id="42-1B"></td><td id="42-1C"></td><td id="42-1D">As clinically indicated</td><td id="42-1E"></td><td id="42-1F"></td><td id="42-1G">✓</td><td id="42-1H">Every 12 mo</td></tr>
<tr><td id="42-1I">Vitamin B₁₂ and folate</td><td id="42-1J"></td><td id="42-1K"></td><td id="42-1L">As clinically indicated</td><td id="42-1M"></td><td id="42-1N"></td><td id="42-1O">✓</td><td id="42-1P">Every 6-12 mo</td></tr>
<tr><td id="42-1Q">TSH</td><td id="42-1R"></td><td id="42-1S"></td><td id="42-1T"></td><td id="42-1U">As indicated</td><td id="42-1V"></td><td id="42-1W"></td><td id="42-1X">Every 12 mo</td></tr>
<tr><td id="42-1Y">Carnitine</td><td id="42-1Z"></td><td id="42-20"></td><td id="42-21">No guideline for adults</td><td id="42-22"></td><td id="42-23"></td><td id="42-24" colspan="2">✓ Pediatric patients Every 3–12 mo</td></tr>
</table>
ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CBC, complete blood count; INR, international normalized ratio; PN, parenteral nutrition; PT, prothrombin time; PTT, partial thromboplastin time; TSH, thyroid-stimulating hormone.
Reprinted from Worthington P, Balint J, Bechtold M et al. When is parenteral nutrition appropriate?
JPEN J Parenter Enteral Nutr. 2017; 41:324-77.

<a id='5689aec4-ef8a-48d7-9026-4da72ffa4738'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='78c576fe-e7d5-4da4-9758-687b825866b2'></a>

CAPTION ERROR

<a id='9c79925d-eca3-44e4-913b-9200671e0fa8'></a>

43

<a id='7f0713b1-f801-41ca-ac3d-7542d2c438b8'></a>

36

<a id='c46c17c4-85f5-41b7-b52f-8d4957add722'></a>

&#169; 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='c52529c4-9973-46f5-a251-51aa0f358791'></a>

CAPTION ERROR

<a id='91297e6e-1757-411e-a3b3-84cf3dfe6a60'></a>

PN Errors

*   Two deaths from Ca/Phos precipitate
*   Death from HPN patient receiving PN with final dextrose concentration of 50%
*   Infant fatally overdosed with dextrose
*   Infant fatally under dosed with dextrose
*   Irreversible neonate brain damage from PN with no dextrose
*   Iron overload and liver toxicity in child receiving iron dextran in PN

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='fee03c27-8a55-4fda-b4d6-5fb7c1aeb679'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='f90d2a87-51a7-4a17-8a10-9016ca56435b'></a>

CAPTION ERROR

<a id='c32ea385-383f-4dff-bb9d-a56c073de527'></a>

Med-MARX® Database Severity Scale

<table id="43-1">
<tr><td id="43-2">Severity</td><td id="43-3">Description</td></tr>
<tr><td id="43-4">A</td><td id="43-5">Circumstances or events that have the capacity to cause error</td></tr>
<tr><td id="43-6"></td><td id="43-7">An Error occurred:</td></tr>
<tr><td id="43-8">B</td><td id="43-9">Did not reach the patient</td></tr>
<tr><td id="43-a">C</td><td id="43-b">Reached the patient but no resulted in no harm</td></tr>
<tr><td id="43-c">D</td><td id="43-d">Required monitoring to confirm that it resulted in no harm and/or required intervention to prevent harm</td></tr>
<tr><td id="43-e">E</td><td id="43-f">May have contributed to or resulted in temporary harm or required intervention</td></tr>
<tr><td id="43-g">F</td><td id="43-h">Contributed to or resulted in temporary harm and required initial or prolonged hospitalization</td></tr>
<tr><td id="43-i">G</td><td id="43-j">Contributed to or resulted in permanent harm</td></tr>
<tr><td id="43-k">H</td><td id="43-l">Intervention required to sustain life</td></tr>
<tr><td id="43-m">I</td><td id="43-n">Resulted in patient death</td></tr>
</table>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
National Coordinating Council for Medication Error Reporting and Prevention (NCC-MERP)
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='f039d74f-8079-42c5-aaab-47575709c14e'></a>

aspen

LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION

American Society for Parenteral and Enteral Nutrition

<a id='e7a1cf6e-0cd5-458d-97a8-5613ca82bbb0'></a>

74

<a id='eaab4c54-0e0d-4a99-a1eb-460f4bada028'></a>

37

<a id='38451e4a-0789-4140-b3c1-0512d18eb364'></a>

44

<a id='397f5d74-13d3-46d5-ad78-ab4c00e84bbd'></a>

CAPTION ERROR

<a id='e8db6a9f-3ca5-4e66-8559-61e7f64ea2a9'></a>

PN Errors Reported to Med-MARX® by
Node and Ingredient

<table id="44-1">
<tr><td id="44-2">Node</td><td id="44-3">Severity, N A-D</td><td id="44-4">Severity, N E-I</td><td id="44-5">Type</td></tr>
<tr><td id="44-6">Ordering</td><td id="44-7">472</td><td id="44-8">8</td><td id="44-9">Improper dose, omisson of dose</td></tr>
<tr><td id="44-a">Transcribing</td><td id="44-b">360</td><td id="44-c">3</td><td id="44-d">Omisson of dose, prepared incorrectly</td></tr>
<tr><td id="44-e">Compounding</td><td id="44-f">90</td><td id="44-g">1</td><td id="44-h">Deteriorated product, omission</td></tr>
<tr><td id="44-i">Administration</td><td id="44-j">487</td><td id="44-k">10</td><td id="44-l">Expired drug, deteriorated product, omission</td></tr>
<tr><td id="44-m">Ingredient</td><td id="44-n"></td><td id="44-o"></td><td id="44-p"></td></tr>
<tr><td id="44-q">Dextrose</td><td id="44-r">21</td><td id="44-s">3</td><td id="44-t"></td></tr>
<tr><td id="44-u">Fat Emulsion</td><td id="44-v">254</td><td id="44-w">3</td><td id="44-x"></td></tr>
<tr><td id="44-y">Electrolyte</td><td id="44-z">92</td><td id="44-A">2</td><td id="44-B"></td></tr>
<tr><td id="44-C">Other</td><td id="44-D">74</td><td id="44-E">5*</td><td id="44-F">*Preparation, administration, ordering and administration</td></tr>
</table>

*Insulin was the most frequent in the 'Other' category related to more harmful events.
Story MA et al. Nutr Clin Pract 31(2);211, 2016

<a id='f46ac161-9b2e-4e4b-a3dd-fc83794b4c8a'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='474f21c3-debd-433b-bc9a-eaee80752be3'></a>

CAPTION ERROR

<a id='c8e37195-562e-4043-b3e5-a32ec68dc729'></a>

Stability

*   The degradation of nutritional components that change their original characteristics.
*   Also, additives maintaining chemical integrity and pharmacologic activity.
*   Maillard reaction – brown discoloration
*   Photodegradation
    *   Vitamins

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='7b16ae40-7f93-4327-8a14-cb800ce82923'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='d2af9aaa-0437-43a5-a53c-4942c72799be'></a>

CAPTION ERROR

<a id='6e726995-f80a-43b4-a2ed-19a9151f51f0'></a>

CAPTION ERROR

<a id='8064e097-70f5-467d-b236-bed9a7b8c45f'></a>

CAPTION ERROR

<a id='ed1f9cde-35dd-4aa7-8663-a3ccfffbd566'></a>

CAPTION ERROR

<a id='4b22b911-178c-46a9-a58b-742510feea67'></a>

TNA Stability

<a id='e82dda77-0f09-45ea-b005-82586147d184'></a>

The following will compromise TNA stability.

Amino Acids
* Final concentration < 4%

Dextrose
* Final concentration < 10%

ILE
* Final concentration < 2%

High cation concentrations
* More than 20 mEq/L of divalent cations (Ca++, Mg++)
* Addition of iron dextran

Admixture of dextrose with ILE before adding amino acids

<a id='b44cdd98-ccd7-4650-8ab6-8f3392e82756'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='9065c426-e138-4e16-a5ee-3e3765999e6a'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='a2218a9b-16b1-46db-a65e-652cb0eee64a'></a>

CAPTION ERROR

<a id='2342c646-a8dc-4701-a7c2-ddf8f223a4ba'></a>

Stability of ILE and TNA

* ILE consists of interior oil phase dispersed in external water phase
* There is a negative charge on the surface of the fat droplet
* When the charge becomes less negative, fat globules form that can lodge in the pulmonary vasculature
* pH 6 – 9 is most favorable
  * When pH is <5 or > 10 this can cause cracking
  * Monitor crystalline amino acid solution use
  * Do not add concentrated dextrose directly to ILE
  * Combine dextrose with amino acid first

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='2a98a975-cd22-4bae-b655-06cc698ac987'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='bddaaf3d-7d56-482c-b32a-1b1bee070c06'></a>

CAPTION ERROR

<a id='5141c8be-da49-4786-a5bb-7a2ef953cd72'></a>

CAPTION ERROR

<a id='8755bf47-af22-4b26-b466-614d83484756'></a>

CAPTION ERROR

<a id='a01c537e-6735-4b3f-9c4c-a0ff63b9e522'></a>

8/5/2025

<a id='f447dba3-90d2-4427-8542-db10933294d2'></a>

## Compatibility

*   Involved the formation of precipitates
*   Most studies evaluate only physical compatibility
*   Review physical compatibility charts (Y-site)
    *   This does not mean a medication can be added to PN

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='b1c12ade-09b3-467f-982f-aa04164fb6b3'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='bb2f4a43-e8fe-4fa6-9562-773b5029defc'></a>

79

<a id='266003ed-1457-4024-8648-fcd11edb1d33'></a>

# Calcium and Phosphorus Stability

*   Lower pH favors the more soluble monobasic calcium phosphate
*   Calcium gluconate preferred
*   L-cysteine can decrease pH
*   Minimize large calcium doses
    *   Confirm doses > 2 times RDA
    *   Hypoalbuminemia, fluid status, acid-base status
*   Add phosphate first, add calcium last
*   Store refrigerated

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='58b79ebb-7fc5-40c6-99c5-ab37d7e8a351'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='5406b063-4c12-4741-a30a-6e4d95dac10f'></a>

CAPTION ERROR

<a id='79cbb154-bb76-4aa5-8496-e01844a1901d'></a>

CAPTION ERROR

<a id='efa788d1-fb8f-430e-9d2b-33a201f32598'></a>

CAPTION ERROR

<a id='1f3e3fb5-cb2f-412c-a2cf-732d657eb0a8'></a>

8/5/2025

<a id='9e4769f0-8018-4ddd-84cf-ce62e554b05d'></a>

DOI: 10.1002/ncp.11189

---

REVIEW

aspen
AMERICAN SOCIETY FOR
PARENTERAL AND ENTERAL NUTRITION

<a id='8da0a085-1570-466e-8b5d-daf539b7aa39'></a>

# Parenteral nutrition compatibility and stability:
Practical considerations

Joseph I. Boullata PharmD, RPh¹ | Genene Salman PharmD² |
Jay M. Mirtallo MS³ | Todd W. Canada PharmD⁴ Ⓓ | Jessica Monczka RD, LD⁵ |
Kathleen M. Gura PharmD⁶ Ⓓ | Paul Kiritsy MS, PharmD, RPh⁷

<a id='f2503b30-91cd-44a0-b806-755c981bf20a'></a>

Nutr Clin Pract. 2024;1-14.

<a id='cc6448d4-353a-4ab3-8b8c-866dff1128d6'></a>

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='b4c049e9-7932-4db2-9ce6-98806b4e23ec'></a>

CAPTION ERROR

<a id='61490714-ebce-45fc-a839-cbf2eceda64d'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<table>
  <caption>TABLE 1 Examples of concentration limits.</caption>
  <thead>
    <tr>
      <th colspan="2" style="background-color:#e0e0e0;">To avoid TNA instability</th>
    </tr>
    <tr>
      <td colspan="2">Example 1<sup>25</sup></td>
    </tr>
    <tr>
      <th>PN component product</th>
      <th>Concentration</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Amino acids injection (Aminosyn II 15%)</td>
      <td>4%–7%</td>
    </tr>
    <tr>
      <td>Dextrose (dextrose 70%)</td>
      <td>10%–20%</td>
    </tr>
    <tr>
      <td>ILE (Liposyn III<sup>a</sup> 20%)</td>
      <td>2%–5%</td>
    </tr>
    <tr>
      <td>Divalent cations (sum of calcium and magnesium)<sup>b</sup></td>
      <td>4–20 mEq/L</td>
    </tr>
    <tr>
      <td>Monovalent cations (sum of sodium and potassium)<sup>c</sup></td>
      <td>0–150 mEq/L</td>
    </tr>
    <tr>
      <td>Phosphate (as sodium and potassium)</td>
      <td>15 mmol/L</td>
    </tr>
  </tbody>
</table>

Nutr Clin Pract. 2024;1-14.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='9c18fa48-1021-4ad4-a8bb-3f80144b07e5'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='58db09e9-acba-4ca5-a802-61d57ad9abe9'></a>

CAPTION ERROR

<a id='00ac7462-0c11-45a9-82b4-f171955bf9b8'></a>

CAPTION ERROR

<a id='cf7f3e7c-820f-4bcd-8ae6-74eaa7a4084c'></a>

CAPTION ERROR

<a id='ddf3d471-e4d0-446c-b5bc-13aca9ef459d'></a>

©2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='39c7ca95-a8a7-4a34-b442-6b5fb6b8a262'></a>

CAPTION ERROR

<a id='ad34e5f7-2496-4072-98a1-85828b6067f1'></a>

# Ca-Phos Solubility Curve

Figure 1. Composite curve for compatibility of calcium (as gluconate) with phosphates at 20-25 °C and pH 6.3 in 25% dextrose injection and 4-4.25% amino acids injection. The farther concentrations are below the curve, the greater the probability of nonprecipita- tion is, and the closer to or farther above the curve concentrations are, the greater the probability of precipitation of CaHPO₄ is.

<::A scatter plot showing Calcium (meq/L) on the y-axis, ranging from 0 to 50, and Phosphates (mmol/L) on the x-axis, ranging from 0 to 25. Data points are plotted, generally showing a decreasing trend of Calcium as Phosphates increase.
: chart::>

Newton D, Driscoll D. Calcium and phosphate compatibility: Revisited again.
AJHP. 2008; 65:73-80.

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<a id='275b9c07-6cb3-4812-b4f2-dbb18925733c'></a>

CAPTION ERROR

<a id='dc7900b7-b270-49ed-bd70-63d1d4cdbade'></a>

Visual Inspection

*   2 in 1 PN
    *   Able to see solid precipitates
*   3 in 1 PN
    *   Cracking
    *   Creaming
    *   Coalescence
    *   Aggregation

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.
aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='a525fcc9-0eab-4b5f-a610-83bfad9ba8c8'></a>

pen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='4a323060-6945-4057-8441-8779bb854060'></a>

CAPTION ERROR

<a id='26e9f213-4c73-4485-a4d7-9bdee20afdae'></a>

CAPTION ERROR

<a id='8900aff5-0b06-4e37-9c75-4e2f87fac6fd'></a>

CAPTION ERROR

<a id='6261f41b-eff8-45e5-b75b-347816d62d86'></a>

CAPTION ERROR

<a id='df4abb44-f51b-4ff4-b68e-e3dc2417c0f0'></a>

<table id="49-1">
<tr><td id="49-2" rowspan="7">© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.</td><td id="49-3"></td><td id="49-4" colspan="4">Table 4. Phases of Lipid Injectable Emulsion Physical Destabilization. 16,17,30</td></tr>
<tr><td id="49-5"></td><td id="49-6">Phase of Destabilization</td><td id="49-7">Definition</td><td id="49-8">Visual appearance</td><td id="49-9">Consequences</td></tr>
<tr><td id="49-a"></td><td id="49-b">Aggregation (flocculation)</td><td id="49-c">Process by which dispersed droplets come together but do not fuse</td><td id="49-d">Particle size may be too small to visualize but may begin to reach the USP threshold</td><td id="49-e">May be redispersed with gentle agitation and used safely</td></tr>
<tr><td id="49-f"></td><td id="49-g">Creaming</td><td id="49-h">Formation of a layer of aggregates at the emulsion surface</td><td id="49-i">A translucent phase appearing at the bottom of the emulsion</td><td id="49-j">May be redispersed with gentle agitation and used safely</td></tr>
<tr><td id="49-k"></td><td id="49-l">Coalescence</td><td id="49-m">A fusion of droplets leading to fewer droplets and increase in droplet size</td><td id="49-n">Contains large droplets from 5 to 50 µm. Visualized as a presence of yellow-brown oil droplets at or near the TNA surface. Free oil may exist as individual spherical droplets or as segmented discontinuous oil layers</td><td id="49-o">Cannot be fully redispersed. Unsafe to use</td></tr>
<tr><td id="49-p"></td><td id="49-q">Oiling out (crack)</td><td id="49-r">Coalescence continues to a point of complete separation—oily layer is seen at the top</td><td id="49-s">Appears as a yellow-brown liquid at the surface of the TNA readily discernable from the remainder of the TNA; can be accompanied by marbling or streaking of the oil throughout the formula</td><td id="49-t">Unsafe to use</td></tr>
<tr><td id="49-u" colspan="2">Nutr Clin Pract 2020;00:1-14</td><td id="49-v" colspan="2"></td><td id="49-w">asp</td></tr>
</table>

<a id='162a2c8a-4103-44d2-ac1a-142a6483336e'></a>

CAPTION ERROR

<a id='7d9df18e-194e-43a7-8938-9afe6250d40d'></a>

© 2025 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved.

<::transcription of the content
: figure::>
Cracked, Example 2: Image of a medical bag containing white liquid with a distinct yellow layer at the top, labeled 'Baxter'.
Heavy Creaming: Image of a medical bag containing white liquid with a thick, creamy layer at the top, labeled 'Baxter'.
Cracked, Example 1: Image of a medical bag containing white liquid with yellow, curd-like particles dispersed throughout, labeled 'Baxter'.
Marbled: Image of a medical bag containing a light yellow, marbled liquid, labeled 'Baxter'.
Image of a medical bag containing a yellow liquid with volume markings and clear layer separation, labeled 'Baxter'.
<::

aspen
LEADING THE SCIENCE AND
PRACTICE OF CLINICAL NUTRITION
American Society for Parenteral and Enteral Nutrition

<a id='21397af9-672b-43d3-a8ef-5f6760e44919'></a>

CAPTION ERROR

<a id='6b434775-aea9-42b4-a240-81ae5ac4ea7f'></a>

50

<a id='e4d21448-c641-459b-9fdb-97f51ef6e808'></a>

CAPTION ERROR